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Tissue engineering holds great promise for treatment of valvular diseases. 
Scaffolds for engineered heart valves must function immediately after implantation, but 
must also permit repopulation with autologous host cells and facilitate gradual 
remodeling.  
Native aortic heart valves are composed of three layers, i.e. two strong external 
fibrous layers (ventricularis and fibrosa) separated by a central, highly hydrated 
spongiosa. The fibrous layers provide strength and resilience while the spongiosa layer 
facilitates shearing of the external layers. Our working hypothesis is that partially cross-
linked collagen scaffolds that closely mimic the layered histo-architecture of the native 
valve would fulfill these requirements. To test this hypothesis we have developed heart 
valve-shaped tri-layered constructs based on collagen, the major structural component in 
natural heart valves. We describe here the development and characterization of two types 
of scaffolds, namely the fibrous scaffolds prepared from decellularized porcine 
pericardium and spongiosa scaffolds from elastase-treated decellularized pulmonary 
arteries. Fibrous scaffolds were cross-linked with penta galloyl glucose (PGG) to control 
remodeling. In order to assemble the scaffolds into a 3D valve structure and form the tri-
layered leaflets, we developed a bio-adhesive consisting of mixtures of bovine serum 
albumin and glutaraldehyde (BTglue) and an efficient method to reduce aldehyde 
toxicity. Glued fibrous scaffolds were tested in vitro for biocompatibility (cell culture) 
and degradation (collagenase and proteinase K digestion). Tri-layered constructs were 





In current studies, we have confirmed that scaffolds glued with BTglue were non-
cytotoxic, with living cells spread across the entire surface of the BT-glue test area and 
cells growing directly on to the glued surfaces. With the long term aim of our studies 
being to create anatomically correct scaffolds to be used as personalized constructs for 
heart valve tissue engineering, we created silicone molds from porcine aortic heart valves 
and then modeled decellularized porcine pericardium into anatomically correct scaffolds. 
After drying them in their molds, the scaffolds have acquired the shape of the aortic valve 
which could then be preserved by exposure to PGG. After inserting decellularized 
pulmonary artery between the fibrous scaffolds to mimic the spongiosa layer, 
functionality testing of the heart valve-shaped scaffolds in a custom-made bioreactor 
showed good leaflet coaptation upon closure and good opening characteristics. Stem cell-
seeded scaffolds also showed cellular differentiation into valvular interstitial-like cells 
(VICs) in similar bioreactor studies.  
Future studies are needed to perfect the assembly process of the tri-layered 
construct. Additionally, further evaluation of stem cell differentiation is needed to 
confirm the presence of VICs in the aortic valve. If successful, there is potential that this 
approach of layering collagenous scaffolds into tri-layered constructs that mimic the 
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Replacement or regeneration of aortic heart valves, exquisite examples of 
durability, design and adaptability, has challenged engineers and surgeons for the last 50 
years. Current treatment of valvular pathology is surgical replacement with mechanical 
valves, valves made from biological tissues or human allografts, but these devices have 
functional limitations, such as the need for life-long anticoagulation, risks of developing 
endocarditis and propensity to degenerate and calcify [1].  
Native aortic valve leaflets are complex structures composed of external layers, 
the fibrosa (composed of collagen) on the arterial aspect and the ventricularis (collagen 
and elastin) on the ventricular aspect. The fibrous layers are sustained internally by a 
highly hydrated central spongiosa layer (rich in proteoglycans) that serves as a cushion 
material to mediate deformations of the fibrous layers, allows shearing between the outer 
layers and absorbs compressive forces during valve function [2-4]. Lack of a buffering 
layer results in large shear stress and tissue buckling when subjected to bending [5].  
The predominant cell populations in heart valves are valvular interstitial cells 
(VICs) which continuously secrete matrix components as well as matrix degrading 
enzymes that mediate remodeling [6-8]. VICs exhibit a dynamic phenotypic spectrum 
ranging from quiescent fibroblast-like cells (characterized by expression of vimentin and 
low expression of alpha-smooth muscle cell actin), to activated VICs, assimilated as 
 2 
myofibroblasts (characterized by proliferation, migration and high expression of alpha-
smooth muscle cell actin) [1, 9-12].   
Tissue engineering, the science of combining scaffolds, cells and specific signals 
to create living tissues is feasible and holds great promise for treatment of heart valve 
disease [13]. Two main strategies have been developed in recent years. The first is based 
on use of decellularized porcine valves followed by in vitro or in vivo repopulation with 
cells of interest. Despite their excellent mechanics, acellular valves are very dense and 
thus difficult to repopulate with desired cells. The second approach employs cell seeded 
polymeric biodegradable matrices [14] or scaffolds built from fibrin [15]. While 
polymeric and fibrin-based scaffolds have shown very promising results, these 
degradable matrices have insufficient strength to withstand arterial pressures immediately 
after implantation.  
Our novel strategy relies on use of stabilized collagen scaffolds that mimic the 
natural valve fibrous layers, based on decellularized porcine pericardium [16] and 
delicate, highly hydrated porous collagen scaffolds to be used as the middle spongiosa 
layer. Chemically stabilized pericardium has outstanding mechanical properties, a good 
record of implantation in humans as valves, and as reconstructive surgery biomaterial 
patches in other organs [17-23]. To reduce scaffold biodegradation, we have also 
investigated the use of penta-galloyl glucose (PGG), a naturally derived collagen-binding 
polyphenol [16, 24]. No reports to date have documented the use of PGG-stabilized 
acellular pericardium for construction of tissue engineered heart valves. Since the 
xenoantigen Gal1-3Gal (Gal), is responsible for rejection of vascularized organ 
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transplants we are also paying special attention to Gal detection in decellularized 
scaffolds [25-29]. 
Recognizing the outstanding mechanical performance of natural valve 
homografts, the vital importance of the three leaflet layers [30], and the need for 
reconstruction of the physiologic valve design, we developed five building blocks for this 
new approach: a) partially stabilized collagenous scaffolds which degrade slowly with 
time, b) anatomically analogous 3-D heart valve shapes made from solid molds, c) tri-
layered constructs that mimic the native heart valve histo-architecture, d) autologous 
multipotent mesenchymal stem cells for repopulation and remodeling and e) mechanical 
cues to induce stem cell differentiation into valvular cells capable of maintaining matrix 
homeostasis.  
Cell sourcing for seeding heart valve scaffolds includes differentiated cells 
(smooth muscle cells, fibroblasts) and mesenchymal or embryonic stem cells [31, 32]. 
Other cell sources include peripheral blood and human umbilical cord blood [33]. Upon 
biochemical and/or mechanical stimulation, most of these cells express markers of 
quiescent VICs such as vimentin, among others [34]. We have chosen to investigate bone 
marrow-derived stem cells as a possible source for stem cells.   
To assemble the 3D heart valve structures we developed and implemented the use 
of biological adhesives for tissue engineering purposes. At a minimum, these adhesives 
need to exhibit adequate bond strength and elasticity, long term stability and 
biocompatibility. We chose to implement a modified albumin/glutaraldehyde adhesive 
for the construction of living heart valves. We describe the development and extensive 
 4 
characteristics of novel scaffolds to be used as the acellular fibrous pericardial scaffolds 
used to mimic the fibrosa and ventricularis, the amorphous pulmonary artery scaffolds to 
be used as the spongiosa layer, and utilization of a biological glue to assemble the tri-
layered constructs. We also show that bioreactor conditioning of stem cell-seeded tri-
layered valves induced differentiation into VIC-like cells.     
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2.1 Physiology of Native Heart Valves 
The heart provides unidirectional flow of blood through the body’s circulatory 
system (Figure 2.1).  This is due to the superb structure of natural heart valves. The four 
valves of the heart are excellent examples of optimum durability, design, and 
adaptability. 
                        
Figure 2.1:  The four valves of the heart in systole  [1] 
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The right side of the heart consists of the right atrium, which collects 
deoxygenated blood from the circulatory system, and the right ventricle, which pumps 
this blood to the lungs to be oxygenated. Between these two chambers is the tricuspid 
valve. anchored in its insertions into the annulus by thread-like chordae tendinae [2]. It 
functions to ensure that the blood within the right ventricle is pumped to the lungs rather 
than back into the right atrium during systole. The blood then moves through the 
pulmonary valve, or semilunar valve, which prevents flow of blood from the pulmonary 
trunk back into the right ventricle while the ventricle fills during diastole. 
The left side of the heart has a similar structure to the right. Oxygenated blood 
from the lungs arrives at the left atrium from the pulmonary vein. During diastole, blood 
flows through the mitral valve, into the left ventricle. The mitral valve is unique in that it 
is composed of only two cusps, one anterior and one posterior [2]. Like the tricuspid 
valves, it is associated with an extensive support system anchoring the cusps in place to 
the base of the left ventricle via chordae tendinae [2].  As systole begins, intraventricular 
pressure rises, closing the mitral valve and opening the aortic valve [3]. Like the 
pulmonary and tricuspid valves, the aortic valve also has three cusps, lying at the origin 
of the aorta. Blood flows out the aorta to feed the systemic circulation. As the ventricle 
again begins to relax, the pressure increases to about 120 mmHg, and the aortic valve 
snaps shut and the ventricle begins to fill. By the time the pressure in the aorta drops to 
about 80 mmHg, the left ventricle has begun its contraction to pump another bolus of 
blood and return the pressure to 120 mmHg [4]. 
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The left side of the heart must develop higher pressures than those on the right 
side (Figure 2.2). This possibly contributes to the fact that heart valves on the left side of 
the heart are most often affected by disease. Therefore, further discussion will focus on 
the anatomy and physiology of the aortic valve, which is the most frequently 
diseased and also most commonly replaced of the valves [5]. 
                   
Figure 2.2: Blood flow through the heart and pressures in various segments [4] 
 
 
2.1.1    Native Aortic Heart Valve Structure and Function 
The aortic valve opens and closes approximately 103,000 times each day and 
about 3.7 billion times in a lifetime [6]. In order to create an aortic valve replacement it is 
essential to understand its function, anatomy and morphology of this valve. 
The aortic valve is composed of three semilunar cusps (leaflets) attached to the 
aortic
 
valve ring, referred to as the annulus, at the commisures (Figure 2.3). Valve 
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leaflets have few and only focal blood vessels, likely because valves cusps and leaflets 
are thin enough to be nourished predominately by diffusion from blood [4]. The cusps are 
cup-like, passive soft tissue structures attached to the wall of the aorta, in a region called 
the aortic root. Because
 
of its passive mechanism, the structure of the aortic valve
 
must 
open with minimal pressure differences between
 
the ventricle and aorta [4]. During 
closing, this same mechanism
 
must prevent backflow by perfectly aligning the cusps, 
which
 
must have enough structural integrity to withstand systemic
 
pressures. These 
leaflets open during systole and press against the aortic root wall. When they snap close 
at the start of diastole they meet to create a seal that can prevent backflow even with the 
40 mmHg transvalvular pressure difference [4].  At this point, when the aortic valve is 
closed, the aorta must distort to better comply with the increased pressures, thereby 
decreasing the amount of stress on any one of the cusps. 
In the aortic root, the cusps themselves are attached within the
 
aortic sinuses, with 
each cusp lying in direct apposition to three shallow indentations, known as the sinuses of 
Valsalva [2] (Figure 2.3). These indentations in the aortic root change the fluid dynamics 
of the valve significantly [7]. It is believed that the sinuses cause the formation of 
vortices that aid in valve closure during retrograde blood flow [7]. Because
 
two of these 
sinuses give rise to coronary arteries, they have
 
been conventionally named as the right 
coronary, left coronary
 
and noncoronary sinuses. 
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Figure 2.3:  (A) The three leaflets of the aortic valve [8] and (B) a depiction of an 
individual leaflet and key landmarks [9]. 
 
 
2.1.2    Native Aortic Heart Valve Ultra-structure  
 Native heart valves maintain unidirectional blood flow via a dynamic structure 
with several key characteristics: viability, sufficient strength to withstand repetitive and 
substantial mechanical stress, and the ability to adapt and repair injury by connective 
tissue remodeling [10].  The extreme amounts of cyclic fatigue that these tissues must 
withstand in order to ensure optimum cardiac performance requires a highly organized 
ultra-structure refined for these tasks. The four cardiac valves have microstructural 
similarities, however the aortic valve best illustrates the central features and has served as 
a standard by which to characterize the microstructural and cellular components of the 
valves and how they relate to functional requirements [11]. Microscopically, the aortic 
valve is composed of three distinct layers that adapt to mechanical changes and aid in 
optimum opening and closing during the cardiac cycle: the fibrosa, the spongiosa, and 
the ventricularis (Figure 2.4).  
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Figure 2.4: (A) Cross-sectional view of the aortic valve representing the tri-layered 
architecture of the native aortic valve [12]. (B) shows the normal interstitial cellularity 
(cell nuclei: dark magenta) and the expected layered structure of the leaflet with the 
ventricularis (v) as inflow side, spongiosa (s) as inner layer, followed by fibrosa (f) as 
the outflow side (Movat-pentachrome stain for visualization of the major matrix proteins: 
collagen, yellow; glycosaminoglycans, green-blue; elastin, black.) [10, 13]. 
 
The cuspal layer nearest the outflow surface (closest to the aorta) is known as the 
fibrosa. It is composed primarily of densely packed, circumferentially aligned collagen 
fibers that span the cusp from one commisure to another [11] (Figure 4, 5(A)). The 
collagen fibers provide strength and stiffness to maintain coaptation during diastole, 
when the cusp has maximal area. Thus, the collagen fibers carry the load that the cusps 
are exposed to when the valve is closed and transfer this load to the aortic wall.  
 The middle layer, located between the fibrosa and the ventricularis, is the 
spongiosa. It is composed mostly of glycosaminoglycans (GAGs) and collagen. The 
collagen within this layer is crimped and densely packed with parallel arrangement to the 
free edge of the cusp [14] (Figure 2.5). GAGs are high molecular weight linear 
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polysaccharides composed of a series of repeating, negatively charged, hydrophilic 
disaccharides [15]. The spongiosa has a gelatinous consistency, due in large part to the 
hydrophilicity of the GAG molecules [15, 16]. It is thus easily deformed in the presence 
of shear forces and cushions shock during the valve cycle and is not readily compressed. 
This resistance to compression during bending aids in cuspal mechanics by preventing 
buckling during flexion (systole), which could result in overall cuspal damage [17]. 
 The final layer of the cusp is the ventricularis. It is located nearest the inflow 
surface, adjacent to the left ventricle. The layer consists primarily of radially aligned 
elastin fibers which, when relaxed, pull the collagen fibers of the fibrosa together, 
forming the corrugations on the surface of the leaflet (Figure 2.4(B), 2.5(A)) [17]. In 
general, the elastin in the valve forms an inter-connected matrix that binds the collagen 
bundles, forming an elastin-collagen hybrid within a larger network of interconnected 
collagen fibers [14]. The elastin extends during diastole and contracts in systole to 
minimize cusp area, the net effect being to provide a dampening effect as the valve closes 
and the cusp is stretched to coapt with its two neighboring leaflets [18]. 
 Hence, it can be summarized that the structural layers within the valve are 
arranged such that they are anisotropically oriented, resulting in greater compliance of the 
valve in the radial direction as opposed to the circumferential (Figure 2.5) [17]. As such, 
the valve has unequal mechanical properties in different directions. This allows the cusp 
thickness to vary from 300-700 µm throughout the course of the entire cardiac cycle [19], 
and thus decreases the chance of impeded blood flow. Furthermore, the different 
structural components and their specific functions within each of the layers of the cusps 
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work to transfer stresses that allow for coaptation of the valve. As visualized in the stress-
strain curve in the Figure 2.5, during opening, elastin extends at minimal load during the 
extension of the collagen crimp and corrugations. The collagen in the fibrous layer is 
arranged and fold in a lengthwise manner, and is oriented towards the commisures such 
that this reduces sagging in the cusp centers and conserves maximal coaptation, thereby 
preventing regurgitation [17]. Then, near full closure of the cusp, and thus complete 
collagen unfolding (diastole), the load-bearing element shifts from elastin to collagen 
[17]. Stress rises progressively while coaptation is maintained. Returning to systole, the 
elastin restores the contracted configuration of the cusp and the cycle can begin again. 
Thus, both the macroscopic valve geometry of collagen and elastin and the fibrous 
components within the valve work to transfer stresses caused by the diastolic force to the 
aortic wall and the annulus, minimizing the stresses the cusp itself must continuously 
experience [20]. This is an important concept to consider for tissue engineering of 
heart valves. 
In studies on normal and pathological valves, it has been observed that the main 
determinant of valve stability and durability is the valvular extracellular matrix (ECM), 
comprised of the collagen, GAGs, and elastin [21]. Most of the mechanical strength of 
the valve is provided by collagen, which is comprised primarily of type I, III, and V 
collagen [22]. The quantities of each of these components is conversely determined by 
the valvular interstitial cells (VICs) [10, 23] (Figure 4, (B)). As touched upon earlier, 
heart valve leaflets experience states of mechanical stress during every cardiac cycle, 
such as  
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Figure 2.5:  (A) Cuspal configuration during and ultra-structural arrangement of collagen 
and elastin during systole and diastole for an aortic heart valve and the complementary 
biomechanical effects of each of these ultra-structural components elucidated in the 
stress-strain plot (B) [20] 
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 shear stress due to blood blow and when the valve opens, flexure during opening and 
closing, and tension when the valve closes [10]. The forces act on the valve at a 
microscopic level, translating the forces into biomechanical responses, which are then 
transduced into biochemical responses by VICs that, at a cellular level, induce up or 
down regulation of ECM synthesis [24].  
Another important cell type present in the aortic valve is the valvular endothelial 
cell (VEC). It covers the surface of the valve, maintaining a nonthrombogenic blood-
tissue interface [25]. The next section will provide more information on the valvular 
cells.      
 
2.1.3    Cells of the Native Aortic Heart Valve  
There are two main types of cells present in the heart valve: a layer of cells that 
cover the valve leaflets known as VECs and the inner cells, VICs. Among the VICs, 
some researchers have identified three cellular phenotypes: smooth muscle cells, 
arranged in bundles or just as single cells [26, 27], fibroblasts maintaining the 
extracellular matrix, and cells that have phenotypic features of both fibroblasts and 
smooth muscle cells, referred to as myofibroblasts [28-30]. The unique characteristics of 
the myofibroblasts, expressing both skeletal and cardiac contractile proteins, may be 
central to the lifelong durability of the valve [29]. In adult valve leaflets, the more 
quiescent fibroblast phenotype predominates among the VICs, characterized by the 
expression of vimentin and low expression of α-smooth muscle actin (α-SMA) [24]. 
During development and adaptation due to diseases, the phenotype of the cells is shifted 
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towards a more activated myofibroblast phenotype, characterized by vimentin and α-
SMA coexpression and secretion of proteolytic enzymes that are capable of degrading the 
matrix, mediating matrix remodeling [31]. This is important when considering tissue 
engineering applications because these can be helpful markers to assess (vimentin and α-
SMA) as indicators of an engineered tissue’s potential to remodel. Various types of these 
proteolytic enzymes (MMPs) and their tissue inhibitors (TIMPs) are present in normal 
valve leaflets in a specific profile and on specific locations [32] (see section Valvular 
Repair and Remodeling for further details).  
 Professor Avrum I. Gotlieb recently proposed to categorize five phenotypes that 
represent VICs: embryonic progenitor endothelial/mesenchymal cells, quiescent VICs 
(qVICs), activated VICs (aVICs), progenitor VICs (pVICs), and osteoblastic VICs 
(obVICs), as shown in Table 2.1 [33]. Based on this data, VICs seem to express a variety 
of defined phenotypes associated with remodeling and repair, in balance within a 
functioning valve; changes in this balance can lead to valve pathology. 
When the cells change their phenotype (such as during development and 
adaptation to higher loads), this balance will be shifted towards one enabling matrix 
remodeling. The distribution of the various phenotypes among the valvular interstitial 
cells in the aortic valve leaflet depend on the biological and mechanical 
microenvironment [24].  In the normal adult aortic valve leaflet, fibroblasts are mainly 
found in the ventricularis, while myofibroblasts and smooth muscle cells are usually 
segregated in the fibrosa [34]. A comparable distribution pattern can be found in the 
vascular wall with myofibroblasts and smooth muscle cells in the medial layer and 
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fibroblasts in the adventitial layer. In the case of hypertension, fibroblasts of the 
adventitia convert into myofibroblasts to adapt to the higher mechanical loads [35]. 
 
Classification of VIC Markers and Functions into Five Phenotypes 







Give rise to resident qVICs, possibly 
through an activated stage. EMT can be 
detected by the loss of endothelial and the 




Maintain physiologic valve structure and 







Enter valve or are resident in valve to 
provide aVICs to repair the heart valve, 





α-SMA-containing VICs with activated 
cellular repair processes including 
proliferation, migration, and matrix 
remodeling. Respond to valve injury 
attributable to pathological conditions and 





Calcification, chondrogenesis, and 
osteogenesis in the heart valve. Secrete 
alkaline phosphatase, osteocalcin, 
osteopontin, bone sialoprotein 
 
 
Table 2.1: VIC markers and Classification into Five Phenotypes [37] 
 
This same adaptation process might explain the distribution pattern of cellular 
phenotypes in the aortic valve leaflets.  But due to the pressure difference over the 
leaflets, more smooth muscle-like cells are expected in the fibrosa compared to the 
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ventricularis [24].  Pressure levels may influence differences between pulmonary valve 
leaflets and aortic valve leaflets as well [34] .  
The idea that cells within the valve play major roles in overall valve dynamics 
was further substantiated when a smooth muscle cell system in the leaflets was identified 
[26]. The smooth muscle cells are terminally differentiated and arranged in small bundles 
in the ventricularis, running circumferentially, or as individual cells [27]. Also, 
contractile properties of these VICs were observed [28, 36, 37], as well as sensory nerve 
elements in the leaflets [38]. Therefore, active contraction of the smooth muscle cells 
within the leaflets might help to sustain the hemodynamic forces that are exerted on the 
leaflets during systole and diastole, either by assisting the valve in opening or to provide 
support during diastole [27, 37], and represents a reactive cytoskeleton that can anchor 
collagen fibrils during valve closure [28].  
The endothelial cells covering the surfaces of the leaflets provide a protective, 
non-thrombogenic layer.  It is noteworthy that the endothelial cells on the leaflets are 
aligned perpendicular to the direction of the flow, as opposed to the alignment of 
endothelial cells in the direction of the flow in blood vessels.  This indicates that a 
mechanical force, other than flow, induces this endothelial cell alignment on the leaflets. 
As the alignment is similar to the alignment of the collagen fibers, it has been 
hypothesized that the pressure stresses during diastole, responsible for the alignment of 
the collagen fibers, are responsible for the alignment of the leaflet endothelial cells. The 
only spot where the endothelial cells align in the direction of the flow is at the nodulus 
[39]. 
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Therefore, it can be concluded that both the VIC and VEC cells within an aortic 
heart valve perform active and dynamic functions that contribute to the overall structural 
integrity and functionality of the heart valve. Thus, when considering tissue 
engineering applications, these cell types and their distribution must be considered. 
 
2.2       Heart Valve Disorders 
Valvular heart disease, or valvulopathy, is the generic name given to any 
dysfunction or abnormality of one or more of the heart’s four valves. According to the 
American Heart Association’s 2006 Heart and Stroke Statistical Update, valvular heart 
disease is responsible for nearly 20,000 deaths each year in the United States and is a 
contributing factor in about 42,000 deaths. The majority of these cases involve disorders 
of the aortic valve (63 percent) and the mitral valve (14 percent) [40], making the 
research of treatments for aortic valve disorders an important field. When considering 
tricuspid valve disease, it affects about 0.8% of the general population in the United 
States [41], most commonly secondary to left-side valve disease, particularly mitral valve 
disease [42]. 
Most experts assert that patients with chronic aortic valve disease can be divided 
into three primary groups: inflammatory, which includes septic and rheumatic lesions, 
congenital, and degenerative [43].  Ultimately, however, the resulting pathology is 
stenosis, insufficiency (regurgitation), or a combination of both [44]. Stenosis is defined 
as the failure of a valve to open completely, thereby impeding forward flow and is most 
commonly a result of a cuspal abnormality [45-47]. Insufficiency, regurgitation, or 
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incompetence, in contrast, results from failure of a valve to close completely, thereby 
allowing reversed flow, and is most often a result of failure of the valves supporting 
structures, such as the ventricular wall or the chordae tendinae [45-47]. Dysfunction may 
vary in degree from slight and physiologically unimportant to severe and rapidly fatal, 
with the 1-year survival rate in patients with severe tricuspid regurgitation is 
approximately 60% [48, 49]. Therefore, intervention is in most cases required. 
 
2.2.1    Congenital and Acquired Abnormalities 
 Even though many patients are asymptomatic, roughly 300,000 patients 
worldwide have some type of surgical intervention to treat malfunctioning valve annually 
[42]. However, in children and infants, the prospect of surgical intervention and potential 
valve replacement poses both technically complex and complicated long-term 
management issues that differ from those of adults [50].  
Of the possible aortic valve dysfunctions, bicuspid aortic valve disease is the most 
common type of aortic valve abnormality [51]. Bicuspid aortic valve disease is a 
congenital condition and occurs in about two percent of the population [52]. Instead of 
the normal three leaflets or cusps, the bicuspid aortic valve has only two. Without the 
third leaflet, the valve may be well-functioning, as for about two-thirds of people who 
have this defect have a bicuspid valve that functions well for life, stenotic, which causes 
the valves to be stiff and therefore leads to the improper opening and closing described 
above, or leaky (regurgitation), because it is not able to close tightly [52]. Patients with 
congenital or bicuspid aortic valve disease often do not require aortic valve surgery until 
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they are adults, however younger patients usually do experience a leaky valve [52]. The 
leaky valve can lead to insufficiency and peripheral circulatory problems, therefore it is a 
condition that cannot be ignored. 
 
              
Figure 2.6: (A) Normal, tricuspid aortic valve. (B) Congenital, bicuspid aortic valve [51] 
 
As stated previously, valvular heart disease, particularly in infants and children, is 
either congenital or acquired. Congenital abnormalities, including structural defects, such 
as the bicuspid valve described above, whether it be a fused, absent, or extra valve leaflet, 
and annulus hyperplasia, can be due to abnormal embryonic development. In all, 
cardiovascular malformations are the most common congenital abnormality, affecting 4 
to 6 in 1000 births, with valve defects accounting for up to 30% of these deficiencies [53, 
54]. On the other hand, acquired valvular disease, referring to pathologic changes caused 
by inflammatory or degenerative processes, could result from diseases such as infective 
endocarditis or acute rheumatic fever [50]. These, however, are less common than the 
congenital bicuspid valve described above. 
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2.2.2    Age-related Abnormalities 
In addition to the congenital and acquired dysfunctions, there are age-related 
issues associated with valvular disease witch increases in prevalence with advancing age, 
afflicting 4% of the population by age 80 years [55]. In particular, one must consider 
calcific aortic stenosis. The natural progression of this condition has shown that severe 
symptomatic aortic stenosis is associated with a life expectancy of less than 5 years [56]. 
But despite the high prevalence of this condition, little is known regarding the molecular 
basis of calcific aortic stenosis (Figure 2.7).  
 
Figure 2.7:  (A) shows an aortic valve with senile calcific aortic stenosis [57] and (B) a 
severely calcified aortic valve [58] 
 
 
Studies have determined that mature lamellar bone formation occurs in calcified human 
aortic valves and that these valves express osteopontin, a bone matrix protein important 
in the development of cardiovascular calcification [59, 60]. Furthermore, it has  have also 
been shown that human aortic valve cell cultures in vitro contain a calcifying cell 
population possessing osteoblast-like features [59]. While some have studied this 
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condition, it is still a significant problem for both aging and bioprosthetic heart valves, as 
will be discussed below. 
 
2.2.3    Valvular Repair and Remodeling 
In response to valvular injury or insult, interstitial cell proliferation and migration 
occurs-the first events of valve repair [61, 62]. The migration is likely directed by the 
activation of integrins and other cell-surface receptors that control cell-ECM adhesion 
[52]. Signaling mechanisms further determine how cytoskeletal proteins react by guiding 
cell spreading, contraction, and translocation, as would be typical in wound healing [19, 
63, 64]. The VICs also play a large part in repair. It has been suggested that the interstitial 
cells may activate from a quiescent state (as described before) to help establish and guide 
a biomechanical response when the valve is exposed to a new mechanical environment, 
as would be expected during injury [19, 23]. This is accomplished by a phenotypic 
change in the VICs, which is determined by the wall stresses in the leaflets [65].  (Please 
recall Aortic Valve Cell section for phenotypic changes, page 17) 
 It is also thought that the interactions between the VICs and the matrix play a 
large part in regulating interstitial cell-based remodeling, including the induction of cell 
migration, the secretion of ECM components, and the secretion of proteolytic 
components- all key parts of the tissue repair process [66]. This is evident by the fact that 
collagenases, gelatinases, and other matrix metalloproteinases (MMPs) have been 
isolated from heart valves [32]. Actually, it is thought that  MMPs and tissue inhibitor of 
metalloproteinases (TIMPs) play a key role in tissue remodeling and regeneration [67, 
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68], with their interactions and the interactions between both the MMPs, TIMPs, and 
their receptors of particular importance in cardiac remodeling [19]. For example, MMP-1 
and MMP-13 have been shown to mediate the initial phase of collagen degradation by 
disassembling the fibrillar collagen native helix, thus contributing to remodeling [66]. 
The fibrillar fragments are then susceptible to other proteases, such as gelatinases, or 
elastases like cathepsin K [69].  And since the level and pattern of MMP and TIMP 
expression in normal valves is very specific [32], excess levels of these proteolytic 
enzymes may cause collagen and elastin degradation and result in weakening or 
destruction of the heart valve. Notably, some valvular pathologies have been associated 
with an over expression of MMPs by the valve’s own cells, leading to ECM degradation 
[65] (Figure 2.8).  
 
 
Figure 2.8: Pathologic valves may have  an abnormal layered architecture: loose collagen 
in fibrosa, expanded spongiosa strongly positive for proteoglycans, and disrupted elastin 
in ventricularis [adapted from 65] 
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These findings may suggest that cells are being stimulated to produce and secrete 
second messengers that prompt native cells to degrade the matrix [70]. Therefore, since 
MMPs are important for remodeling of tissue engineered scaffolds, their activity must be 
tightly regulated and controlled in these situations to prevent deleterious events and valve 
failure. 
 
2.3     Treatments of Valvular Pathology 
Even though there are is no medicinal treatment for valvular disease, a physician 
will most likely recommend medications to control blood pressure and will place 
limitations on strenuous activity (especially lifting heavy objects), particularly for those 
with aortic stenosis. However, if symptoms are present or there is severe ventricular 
dysfunction with either stenosis or regurgitation, further surgical intervention will be 
warranted [71]. 
 
2.3.1   Minimally Invasive Treatments 
In some heart conditions minimally invasive surgical approaches via catheters can 
provide results comparable to those one would expect to experience with surgery. While 
most patients are able to undergo surgery without difficulty, for people whose heart 
function is too severely compromised to withstand surgery, several approaches to treat 
heart valve disease without surgery have been developed. One example is percutaneous 
valvotomy, or valvuloplasty (Figure 2.9) [1].               
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Figure 2.9: Mitral valvotomy [1]. Please see details in text below 
 
Valvotomy can be performed in some patients to treat aortic valve stenosis or 
mitral valve stenosis [72, 73]. During an aortic valvotomy, a catheter is placed through 
the femoral vein (in the groin) and guided into the chambers of the heart. The cardiologist 
then creates a tiny hole in the wall between the heart’s two upper chambers, providing an 
opening for access to the left atrium with a special catheter that has a balloon at the tip. 
The catheter is positioned so the balloon tip is directly inside the narrowed aortic valve 
(Figure 2.9(A)) while the valve opening is dilated by rapidly inflating and deflating the 
balloon (Figure 2.9(B-D)) [1].         
Other investigational options are being explored as alternatives to invasive 
surgical procedures, the first of which is a possible percutaneous aortic valve replacement 
(AVR). Percutaneous AVR is a new treatment being investigated for select patients with 
severe symptomatic aortic stenosis [72]. It is also being investigated as a possible 
technique for implanting a prosthetic valve inside the diseased calcific aortic valve. The 
procedure is performed in the catheterization lab [1, 72]. During the procedure a catheter 
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is placed through the femoral artery and guided into the chambers of the heart. A stent-
mounted, compressed tissue heart valve is placed on the balloon-mounted catheter and is 
positioned directly over the diseased aortic valve. Once in position, the balloon is inflated 
to secure the valve in place (Figure 2.10) [1]. This holds great possibilities as a 
deployment method for tissue engineered heart valves. As such, the implantation 
method must be considered in the design process of the valve. 
                 
Figure 2.10:  Percutaneous aortic valve replacement (AVR) [1]. A balloon catheter is 
placed in the diseased aortic valve orifice (A,B) and is inflated to deploy  the tissue valve 
(C,D) 
 
2.3.2   Surgical Repair Treatments 
There are several options for young adult patients with aortic valve disease. The 
type of aortic valve surgery that is recommended is based on several factors, including 
the age of the patient, the expected long-term survival, any co-existing medical 
conditions including the type of valve disease, other types of heart disease, or other 
medical conditions, certain surgical risks, including the risk of thromboembolism, the risk 
of endocarditis, and the overall durability of the valve [74]. Along with the type of valve 
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chosen comes the risk of bleeding complications with long-term anticoagulation therapy.  
Most adolescent and young adult patients are concerned about aortic valve surgery 
because they want to maintain an active, normal lifestyle, including sports, travel, 
pregnancy, etc., and they wish to avoid the use of anticoagulant medications, which some 
patients are required to take after valve surgery (as for mechanical valves, which will be 
discussed). They also hope to avoid the need for future surgeries, which are in many 
cases necessary. Fortunately, in addition to complete valve replacements, there are other 
options for the treatment of valvular pathologies. One of these options is aortic valve 
repair [75].  Aortic valve repair may be an option for patients who have bicuspid aortic 
valve disease or other aortic valve conditions that are associated with valve regurgitation 
[75]. 
Even though aortic valve repair is not performed very often because it is 
technically very difficult, the majority (two-thirds), of leaky bicuspid aortic valves can be 
repaired with good results [51]. This type of surgery may be advantageous because the 
natural anatomy of the heart, as well as heart muscle strength, is preserved. There is also 
a decreased risk of infection, as opposed to complete valve replacement, and need for 
life-long anticoagulant medication [51, 76-78]. 
                                           
Figure 2.11:  Aortic valve repair of a congenital bicuspid aortic valve, depicting 
shortening of the abnormal cusp [51]. 
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However, there are drawbacks to this type of surgery. For one, this type of aortic 
valve surgery is technically difficult and is really only an option for leaky aortic valves, 
not stenotic valves [75].  Although a repaired valve can possibly last a lifetime, about 20 
to 25 percent of patients will require a valve replacement within ten years [51, 76]. In the 




Figure 2.12: The Ross Procedure- In (1), the measurements of the aortic and pulmonic 
valves are taken, then (2) the aorta and pulmonary artery are opened and the aortic and 
pulmonary valves are inspected to determine if the Ross is an appropriate procedure. 
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Next (3), the diseased aortic valve is removed and the pulmonary valve (autograft) is 
removed and placed in the aortic position. The autograft is sutured in place (4) and the 
coronary arteries are re-attached. A pulmonary homograft is then attached to the right 
ventricle outflow tract (5). Finally, the aorta is attached to the autograft and the 
pulmonary artery is attached to the homograft (6) - the procedure is complete [51]. 
 
 
Another alternative to valve replacement is a procedure known as the Ross 
operation (Figure 2.12 above), or the Switch procedure as it is commonly referred [79]. 
The Ross procedure is usually performed on patients younger than ages 40 to 50 who 
want to avoid taking long-term anticoagulant medications after surgery [79]. During this 
procedure, the patient's own pulmonary valve is removed and used to replace the diseased 
aortic valve. The pulmonary valve is then replaced with a pulmonary homograft [51, 79]. 
This procedure may be an attractive alternative to replacement with mechanical or 
xenogenic tissue valves in the aortic position because the pulmonary valve is 
anatomically very similar to the aortic valve and could be an ideal substitute for the aortic 
valve. Also, as opposed to mechanical valves, the new aortic autograft is a living valve 
and it may grow as the young adult grows, making this a good option for young patients. 
And given that the blood flows with less pressure through the pulmonary valve than the 
aortic valve, a homograft valve could last longer in the right-sided pulmonary valve 
position rather than the aortic position. Furthermore, the risk of thromboembolic 
complications and the risk of valve infection are very low. Moreover, the hemodynamic 
performance makes the Ross operation an attractive alternative for athletes [10, 51]. 
Ultimately, the pulmonary autograft valve has a good chance of being a life-lasting 
solution for the aortic valve (it is speculated that the pulmonary autograft will last a 
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lifetime in at least half the patients that undergo the Ross procedure [79]), making it an 
attractive alternative to conventional valve replacements. 
However, there are drawbacks to this procedure that make it not the most 
attractive option for some patients. The Ross procedure is a technically difficult and long 
surgery, as it requires two valve replacements. As a consequence, this procedure is only 
recommended for young patients who would tolerate a long surgery time [80]. Also, the 
pulmonary autograft valve is transplanted from the low pressure pulmonary circulation 
over to the aortic high pressure system [51]. While the valve cusps are strong enough to 
withstand the systemic pressure, the pulmonary artery wall does dilate when exposed to 
systemic pressure, occasionally enough to cause the autograft valve to leak. Therefore, 
the risk of requiring re-operation for a leaking autograft valve is about 10 percent within 
10 years after the operation [79].  Also, the Ross procedure is not recommended for 
patients with tissue defects (such as Marfan syndrome) or for patients who have an 
abnormal pulmonary valve [80]. The pulmonary homograft in the pulmonary position 
could also fail; the most common reason for failure is that it becomes stenotic. The risk of 
requiring replacement of the pulmonary homograft is about 10 percent within 10 years 
after the procedure[79]. Therefore, while there are surgical options for repairing a 
compromised aortic valve, the risk associated with the surgery and the prospect of 





2.3.3   Heart Valve Replacements and Devices 
As stated previously, valvular heart disease represents a significant cause of 
mortality worldwide. Diseases can affect any of the four heart valves, although diseases 
of the aortic valve occur most frequently, associated with high mortality rates. And when 
the non- surgical and minimally invasive approaches fail to ameliorate the symptoms 
caused by a dysfunctional heart valve, the most common treatment for end-stage valvular 
diseases is surgical replacement of the valve. Historically there have been two types  of 
artificial heart valves that are implanted- mechanical and tissue-based [81, 82].  Today, 
while mechanical valves contribute to approximately 60% of replacements, tissue valves 
are used in 40% or more of valve replacements world-wide, whether as autografts or 
allografts, or more predominantly as stented porcine aortic valve and bovine pericardial 
valves preserved by glutaraldehyde (collectively  termed  bioprostheses) [20]. None of 
these devices, however, is without complications.  
 
 
Figure 2.13:  Images of contemporary valves implanted into patients today. (a) Bileaflet 
mechanical  valve, (b) single leaflet mechanical valve, (c) bovine pericardial 
bioprosthesis, (d) stented porcine xenograft valve, (e) stentless porcine xenograft, and (f) 






2.3.3.1 Clinical Practice 
 The ideal, or ultimate, replacement heart valve would have to function 
immediately after implantation, would have increased durability than the replaced valve, 
would be conductive to repopulation with host cells, and would have remodeling 
potential, or the ability to grow with the patient. Of the currently available replacements, 
no one valve fulfills all the above requirements. However, each has advantages and 
disadvantages over the others. 
 
2.3.3.2 Autografts and Allografts 
Cryopreserved aortic donor valves are the heart valve replacements closest to the 
natural valve, not being thrombogenic and with a low risk of infection.  They are not 
chemically cross-linked and exhibit good mechanical properties, which prolongs their 
lifetime [84]. However, their disadvantages are their limited availability, a more difficult 
implantation technique [85] and failure associated with a specific immune response, 
especially in young children [86]. The use of cryopreserved pulmonary homografts as 
aortic heart valve replacements has been shown to result in early failure as the fiber 
structure of the pulmonary valve is less resistant to the hemodynamic environment in the 
aortic position compared to cryopreserved aortic valves [87]. Furthermore, these valves 
were shown to suffer from gross regurgitation in vitro, only augmenting the underlying 
cause for a replacement [88].  
A controversial issue regarding cryopreserved homografts concerns the viability 
of the native endothelial and interstitial cells. A lack of viable cells after implantation was 
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stated [20] as well as the long-term survival of cellular elements [89]. In general, 
although cryopreservation reduces cellularity, the expression of strong antigens could still 
be demonstrated, and this might trigger the immune system of the host, resulting in graft 
rejection [90]. 
                                       
Figure 2.14: Allograft Valve Replacement- An allograft is an aortic or pulmonic valve 
that has been removed from a donated human heart, preserved, antibiotic-treated, and 
frozen under sterile conditions. A homograft may be used to replace a diseased aortic 
valve, or it may be used to replace the pulmonic valve during the Ross procedure [51]. 
 
 
2.3.3.3 Mechanical Heart Valves 
Mechanical heart valve replacements display good structural durability, but are 
associated with a risk of prosthetic valve endocarditis and high rates of thromboembolic 
complications caused by their non-physiological surface and flow abnormalities[80]. 
Life-long anticoagulation therapy is necessary in these patients, which is associated with 
a substantial risk of spontaneous bleeding or embolism, particularly in patients aged over 
70 years [91, 92]. Mechanical valves are of rigid construction and because of flow 
patterns and material properties, induce blood clotting on their surface.  In the 1960s and 
1970s, some  of  these  valves  failed  catastrophically  by having  a  leaflet  dislodge and 
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flow into circulation (causing embolic complications) or  a  portion  of  the  cage  break, 
which could be fatal [83, 93, 94] (Figure 2.15 below for examples of mechanical valves) 
    
Figure 2.15: (A) and (B) are examples of a ball and cage and disk mechanical valve, 
respectively, which are no longer used, while (C) shows a conventional mechanical heart 
valve in use today [adapted from 95]. 
 
 
Currently, the most serious drawback to the use of mechanical valves is the 
anticoagulation therapy. Chronic anticoagulation is associated with cumulative morbidity 
and mortality, often as high as 4% per year [96, 97], which essentially guarantees some 
serious event within a 25-year implantation period [80]. This is particularly distressing 
for pediatric applications, where there is not only the prospect of multiple surgeries to 
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correct valve malfunctions, but the ever changing myocardium of a young mechanical 
heart valve recipient would necessitate further surgeries to accommodate the growing 
heart 
 
2.3.3.4 Bioprosthetic Heart Valves 
Bioprosthetic heart valve (BHV) replacements are of animal origin (xenografts), 
such as porcine aortic valves and bovine pericardial valves. Xenografts are chemically 
cross-linked - this inhibits autolysis, enhances the mechanical stability, and creates the 
possibility of having valves of different size directly available. However, these valves 
differ in many respects from native valves, for example in their opening and closing 
behavior due to the chemical pre-treatment [20]. Explanted xenografts were shown to be 
stiffer in the radial direction and less stiff in the circumferential direction compared to 
native porcine valves [98]. The risk of thromboembolic complications is much lower, but 
the valve’s durability is limited. Structural failure is strongly age-dependent, making 
xenografts attractive for the elderly, but less suitable for children and young adults [20]. 
One important aspect in xenotransplantation is the risk of zoonoses - human 
diseases caused by infectious agents from animals [99]- which might even be facilitated 
by the mandatory immunosuppression [100, 101], but this is not necessary for BHVs. The 
identification of porcine endogenous retroviruses and prionic diseases has given rise to 
great concern. Recently, epidemiological data have strongly indicated transfer of 
Creutzfeldt-Jakob disease from cattle into humans either via infected meat, via surgical 
materials derived from bovine gut, or via drugs or vaccines prepared using fetal calf 
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serum [102]. Porcine endogenous retroviruses (PERV) can be present in all organs, as 
multiple copies of PERV can be integrated into germ-line DNA. New and more 
infectious groups of PERV are being identified [103], as well as their capacity to infect 
various types of human cells in vitro [104, 105].  One antigen that has been implicated in 
xenogenic transplantation rejection is galactose-alpha(1–3)-galactose (αGal), which are 
carbohydrate  residues  present  on  cell-surface  glycoproteins and glycolipids of porcine 
tissue, but not human tissue [106].  
Xenografts are attractive alternatives to homografts as a replacement for an 
injured valve because sufficient numbers can be obtained [107, 108]. Using the bovine 
pericardium or porcine heart valves in the manufacture of these valves has become 
somewhat standard, but these two tissues differ significantly in both structure and overall 
function. The bovine pericardium is more structurally homogeneous than the porcine 
tissue with respect to collagen and elastic fiber orientation, while the porcine tissue is less 
uniform. However, the porcine valve leaflet does contain a spongiosa layer, like the 
human leaflet and unlike the bovine pericardium. This spongiosa accumulates large 
deposits of proteoglycans that serve to reduce friction between the other two layers, again 
as in the human valve, but upon processing, are usually lost, leaving empty spaces for 
which may serve as sites for hydroxyapatite crystal nucleation, leading to calcification 
[109-112] 
But, as stated for any tissue implant, the immediate problem with these devices is 
the preservation and sterilization of the tissue. Initial fixatives included the use of 
mercury salts and formaldehyde and finally glutaraldehyde (Glut) [109]. Glutaraldehyde 
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is a five-carbon dialdehyde that reacts directly with primary amines on residues of the 
amino acids lysine and hydroxylysine (found in abundance in the collagen of pericardial 
tissue and valves) [113-116]. Since 1970, glutaraldehyde has become the general fixative 
treatment, but there remain a number of problems with these treatments. Although Glut 
bioprostheses mimic natural aortic valve structure, their cells are nonviable and thereby 
incapable of normal turnover or remodeling ECM proteins [20], Glut-fixed tissue is much 
stiffer than natural cup tissue, which can lead to greater internal stresses in bending [117], 
and their mechanical properties are markedly different from those of natural aortic valve 
cusps. Consequently, tissue valves suffer a high rate of progressive and age-dependent  
structural  valve  deterioration  resulting  in stenosis or regurgitation [20].  
Two distinct  processes- intrinsic  calcification  and  noncalcific degradation of 
the ECM account for structural valve deterioration. Calcification is a direct consequence 
of the inability of the nonviable cells of the Glut-preserved tissue to maintain normally 
low intracellular calcium. Calcification begins in the cells as crystalline deposits, then 
nucleation of calcium-phosphate crystals occurs in the collagen and elastin [20, 118]. 
Noncalcific degradation in the absence of physiological repair mechanisms of the 
valvular structural matrix are largely thought to be due to changes to the natural valves 
when they are fabricated into a tissue valve and  the  subsequent  interactions  with  the 
physiologic environment that are induced following implantation[20]. However, the 
advantages include the fact that Glut is efficient as a sterilizing agent against bacteria, 
fungi, and viruses, but one cannot overlook the major problems, that are the propensity of 
Glut-treated tissue to calcify and clear cytotoxic effects that render cells not viable [119]. 
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As a result, numerous experimental chemical treatments, none of which are in 
clinical use, are being addressed to alleviate the shortcomings of Glut. Of these, many 
attempt to stabilize tissue without the use of aldehydes, such as diphenylphosphoryl 
azide, carbodiimide, and hexamethylene diisocyanate [119-121]. Other treatments have 
aimed at impeding the harmful effects of glutaraldehye with subsequent treatments with 
amino acids that block the aldehyde groups [122-127] or pretreatment with chemicals 
(such as neomycin) that specifically target GAGS, that are not at all stabilized with Glut 
[128] and subsequently lost in preparations. Another treatment that was used to prepare 
tissue, in concurrence with Glut, was pressure fixation.  Generally, prostheses made of 
porcine tissue are treated with pressures equivalent to diastolic pressure, but these 
fixation pressures can affect collagen buckling, loss of endothelium, different degrees of 
connective tissue cell autolysis, and the tissue can be rigid and inflexible [129]. 
Therefore, there is a need for a more adequate fixation method that addresses and 
alleviates the shortcomings of the fixatives above. 
 
2.4       Heart Valve Tissue Engineering 
The ultimate goal of tissue engineering is to construct tissues from their cellular 
components which combine and maintain most of the characteristics  of  the  original, 
healthy tissue.  For  a functioning heart valve these include durability, adequate 
mechanical function, which correlates with haemodynamic performance, and a mature 
extracellular matrix which does not elicit an immunogenic or inflammatory reaction. To 
this end, the success  of  tissue  engineered  heart  valves  (TEHV)  is dependent on three 
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main issues: (1) the scaffold, which   determines   the   three-dimensional   shape   and 
serves as an initial guiding structure for cell attachment and tissue development; (2) the 
cell source from which a  living  tissue  is  grown;  and  (3)  the  in  vitro  culture 
conditions of the living construct before implantation [20]. 
In order to overcome the limitations of today’s heart valve replacements, 
researchers have developed different tissue engineering concepts using various scaffold 
materials. These include biodegradable synthetic scaffolds seeded with autologous cells, 
decellularized allo- or xenografts seeded with autologous cells (auto-xenograft) or 
decellularized allo- or xenografts without cell seeding (Table 2) [130].  
         
 
Table 2.2: Scaffolds and their potential use in tissue engineering [130] 
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Several attempts have been made to create functional heart valve replacements with the 
ability to grow, repair, and remodel using the concept of tissue engineering. As 
demonstrated by the schematic representations below (Figure 16, A,B), in one approach 
to tissue engineering, the patient’s own cells, isolated, for example, from a blood vessel 
and expanded using standard cell culture techniques, are seeded on the scaffold, in the 
shape of a heart valve.  
                               
Figure 2.16 (A):  Schematic of  principle of tissue engineering of heart valves.  1) 
Isolation of cells from a blood vessel of the patient and separation of myofibroblasts and  
endothelial cells. 2) Seeding of myofibroblasts onto a scaffold material in the shape of a 
trileaflet heart valve and subsequent seeding of endothelial cells onto the surfaces. 3) The 
cell/scaffold construct is placed into a bioreactor to stimulate tissue development [130]. 
 
 
Subsequent stimulation, transmitted via the culture medium (biological stimuli) or via 
’conditioning’ of the tissue in a bioreactor (mechanical stimuli), promotes tissue 
 44 
development, resulting in a completely autologous, functional, and living heart valve 
implant [20]. However, scaffold seeding has proven to be difficult and incomplete 
and mechanical properties are not comparable with native tissue, so improvements 
must be made. 
Another approach, elucidated by Figure 16 (B), is to implant unseeded scaffolds 
designed to encourage cell migration and proliferation. In either approach, the end goal is 
the same- to promote cell growth on a tissue engineered scaffold whereby the scaffold 
will be incorporated into the body as a living tissue. 
 
 
Figure 2.16 (B):  The paradigm of tissue engineering (Pathway A) The conventional 
paradigm of tissue engineering comprises a scaffold that is seeded with cells, an in vitro 
stage of tissue formation typically conducted in a bioreactor, and an in vivo stage of tissue 
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growth and remodeling. The key processes occurring during the in vitro and in vivo 
phases are cell proliferation, ECM production and organization, scaffold degradation, and 
tissue remodeling. The resulting tissue engineered construct will contain some 
combination of seeded and/or new cells. A modified paradigm (Pathway B) might utilize 
an unseeded scaffold that is fabricated with biological “information” designed to attract 
and provide a suitable substrate for differentiation of circulating precursor cells in vivo 
[10]. 
 
Heart valve tissue engineering represents a promising approach towards 
autologous, living, and functional heart valve replacements with the ability to grow, 
repair, and remodel.  Mechanical conditioning of the developing tissue in a bioreactor has 
rendered heart valve replacements, which have shown excellent functionality in sheep 
when implanted in the pulmonary position [131]. The pulmonary position is, however, 
a low-pressure environment and as most heart valve replacements concern the 
aortic valve, a high-pressure environment, the tissue properties of the neo-tissue 
have to be optimized further to serve as aortic heart valve replacements.  
 
2.4.1   Scaffolds for Heart Valve Tissue Engineering 
As stated previously, the heart valve scaffold may be either based on biological or 
synthetic materials. Donor heart valves or animal derived valves depleted of cellular 
antigens can be used as a scaffold material. Removing the cellular components results in 
a material composed of essentially extracellular matrix proteins that can serve as an 
intrinsic template for cell attachment [132]. In general, non-fixed, acellularized valve 
leaflets have shown recellularization by the host, as demonstrated in dogs [133] and sheep 
[134]. However, first clinical applications of this concept in children resulted in rapid 
failure of the heart valves due to immune rejection as a result of incomplete 
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decellularization, and was associated with a 75% mortality [135]. In a further approach, 
specific biological matrix constituents can be used as scaffold material, including 
collagens and fibrin [136, 137]. These materials have the disadvantage that they are 
difficult to obtain from the patient in sufficient quantities.  Therefore, most of these 
scaffolds are of animal origin. In this context, identification of retroviruses and prionic 
diseases has given rise to great concern as to the risk of zoonoses. 
An ideal synthetic scaffold for tissue engineering applications must be at least 
90% porous [138], and must possess an interconnected pore network, as this is essential 
for cell growth, nutrient supply, and removal of metabolic waste products.  Besides being 
biocompatible, biodegradable, and reproducible, the scaffold should also display a cell-
favorable surface chemistry and, as stated above, match the mechanical properties of the 
native tissue [20]. The rate of degradation should be proportional to the rate of tissue 
formation and controllable in order to ensure mechanical stability over time [139, 140]. 
The use of synthetic materials as scaffolds has already been broadly demonstrated for 
heart valve tissue engineering. Initial attempts to create single heart valve leaflets were 
based on synthetic scaffolds, such as polyglactin, PGA (polyglycolic acid), PLA 
(polylactic acid) and PLGA (copolymer of PGA and PLA). To create complete trileaflet 
heart valve conduits, PHA based materials (polyhydroxyalkanoates) were used [141]. A 
combined polymer scaffold consisting of non-woven PGA and P4HB (poly-4-
hydroxybutyrate) has shown promising results in sheep, when placed in the pulmonary 
position [131]. These materials are thermoplastic and can therefore be easily molded into 
any desired three dimensional shape [130]. These  above materials  are  approved  for 
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surgical use and they are biocompatible and biodegradable. A major advantage  of  
synthetic  matrices  is  the  fact  that  their biodegradation  properties  and  biomechanics  
can  be chemically  designed  according  to  the  requirements of the  particular  
application.  Moreover,  specific  proteins such  as  growth  factors  may  be  incorporated  
into  the scaffold structure enabling targeted promotion of specific tissue growth [130, 
142] . However, success  of  synthetic  leaflet  HVs  has  also  been hampered by their 
impaired haemodynamic performance compared with the performance of natural valves 
[143] and the fact that they have their  limited  durability  are susceptible to calcification, 
which leads to leaflet stiffening and tearing [144]. 
 
2.4.2   Alternative Cross-linking Methods 
 As discussed with bioprostheic valves, tissue engineered valve replacements 
based on biological scaffolds are subject to degradation and stability concerns. And like 
bioprosthetic replacements a possible way to increase the resistance of natural tissue-
engineered scaffolds to proteolytic  degradation  is  to  use  chemical  stabilizing and/or 
cross-linking agents. Several  cross-linking   and   stabilizing   agents (such as 
glutaraldehyde and proanthocyanidin)  and methods have been proposed and tested with 
different degrees of success [152, 153] however the ideal or at least clinically  optimal  
stabilizing  agent  has  not  yet  been identified. 
Recently tannic acid (TA) and tannic acid mimicking dendrimers (TAMD) have 
been suggested as potential cross-linking agents  for  collagen  [154-156]. It  was  also 
shown  that  addition  of  TA  to  glutaraldehyde  (Glut) pretreatment dramatically 
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improves elastin and collagen stabilization in cardiovascular implants as evidenced by an 
increased resistance to   proteolytic   degradation [157]. Moreover, TA has 10 times 
lower toxicity as compared to Glut [157].  
One tannin in particular that is being investigated is penta-galloyl glucose (PGG). 
It is a naturally derived polyphenol present in plants and is currently available in pure 
form from several manufacturers. Structurally, it belongs to the galloyl-glucose family 
(syn. gallotannins), characterized by a D-glucose molecule esterified at all five hydroxyl 
moieties by gallic acid (3,4,5 -trihydroxybenzoic acid) (Figure 17).  
      
 
Figure 2.17: Structure of PGG. Five gallic acid residues (pink dotted lines) are bound to 
each of the hydroxyl groups of a glucose core (blue). At right, spatial configuration of the 
PGG molecule.  
 
This core molecule may be derived by addition of gallic acid, to yield structures that may 
contain a total of 10-12 galloyl residues, also known as tannic acids [158] Polyphenols 
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have a hydrophobic internal core and numerous external hydroxyl groups. By virtue of 
this structure, they react with proteins, specifically binding to hydrophobic regions [159], 
but also establishing numerous hydrogen bonds, showing particularly high affinity for 
Proline-rich proteins[160] such as collagen and elastin [161]. In addition, they inhibit 
many enzymes, are efficient antibacterial agents and reduce inflammation and 
antigenicity [158]. Polyphenols have very low toxicity in animals (LD50 = 6 g/kg, orally 
in mice, LD50 = 700 mg/kg i.p. in rats, LD50 = 80 mg/kg i.v. in rats, as per Merck 
Index). Recently we also showed that peri-arterial delivery of PGG to rat abdominal aorta 
prevented aneurysm formation or progression and did not elicit any detectable changes in 
serum liver enzyme activities or liver histology, clearly showing that PGG was not toxic 
[162]. Moreover, extractables obtained from PGG-fixed tissues exhibited very low in 
vitro cytotoxicity towards fibroblasts and smooth muscle cells (less than 10%)[163] and 
thus can be used safely in tissue engineering applications.  
 
2.4.2   Cell Sources for Heart Valve Tissue Engineering 
 As briefly explained above and visualized in Figure 16 (A), in most 
cardiovascular tissue engineering approaches cells are harvested from donor tissues.  
From peripheral arteries, for example, mixed vascular cell populations consisting of 
myofibroblasts and endothelial cells can be obtained.  Out of these, pure viable cell lines 
can be easily isolated by cell sorters [145] and the subsequent seeding onto the 
biodegradable scaffold is undertaken in two steps. First the myofibroblasts are seeded and 
grown in vitro and second, the endothelial cells are seeded on top of the generated neo-
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tissue leading to the formation of a native leaflet-analogous histological structure [146]. 
With regard to clinical applications, several vascular human cell sources have been 
investigated [147]. Recently, cells derived from bone marrow or umbilical cord have 
been successfully utilized to generate heart valves and conduits in vitro [148-150] 
(Figure 18).  
         
                  
Figure 2.18: Differentiated human umbilical cord cells showing in (A) Hematoxylin-
eosin and (B) Masson’s trichrome staining cells with a fibroblast morphology and 
deposition of extracellular matrix proteins. Immunofluorescence staining demonstrated 
expression of (C) vimentin and (D) alpha-smooth muscle actin [148]. 
 
In contrast to vascular cells, these cells can be obtained without surgical 
interventions representing an easy-to-access cell source in a possible routine clinical 
scenario.  Due to their good proliferation and progenitor potential, these cells are 
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expected to be an attractive alternative for cardiovascular tissue engineering applications. 
Apart from the use of so called progenitor cells, the research on stem cells and their 
differentiation pathways is still in its infancy and a drawback is the possible 
immunogenicity of these cells. This may be solved by genetic engineering [151], 
although this is still in the experimental phase. The best option for stem cell use is to 
use autologous stem cells and, using both mechanical and biochemical cues, 
differentiate these into VICs. 
 
2.4.4   Conditioning of Tissue Engineered Heart Valves 
 Tissue formation can be stimulated by either biological or mechanical 
conditioning. Biological conditioning involves addition of cytokines either directly to the 
growth medium or by incorporation into the scaffold material. Cytokines are a group of 
regulatory molecules that function as mediators of cell communication and can exert 
multiple biological functions by interaction with specific cell surface receptors. The 
family of cytokines includes interleukins, hematopoietic growth factors, interferons, 
tumor necrosis factors, and growth factors [164].  Well-known cytokines that influence 
vascular cell behavior are fibroblast growth factor (FGF), platelet-derived growth factor 
(PDGF), transforming growth factor-β (TGF-β), and vascular endothelial growth factor 
(VEGF) [165, 166] Besides cytokines, regulating cell behavior, matrix metalloproteinases 
(MMPs) play an important role in tissue development and subsequent remodeling [167]. 
When cytokines are directly applied to the growth medium, the effect is short term and 
should be repeated several times.  When incorporated into a biodegradable scaffold 
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material, slow release can be obtained by coupling of the cytokine release to the 
degradation rate. 
Mechanical conditioning involves the application of various mechanical stimuli in 
a bioreactor, such as flows, inducing shear stresses over the developing tissue, and 
strains, being either dynamic or static in nature. For engineering of heart valves, the most 
commonly used bioreactor is a pulse duplicator system, in which the normal opening and 
closing behavior of the valve is mimicked [168, 169]. In this type of bioreactor, the tissue 
is exposed to increasing flow rates and pressures. Recently, new bioreactors have been 
developed for tissue engineering of heart valves, in which the exact physiological 
conditions of a heart valve in vivo can be applied [170-172]. Mechanical and biological 
stimuli do interact in a very complex way in the regulation of tissue behavior.  By 
mechanical stimuli, the production and secretion of various cytokines by the cells are 
increased, or conversely, the addition of cytokines during tissue development can 
increase the effect of mechanical conditioning.  
 
2.4.5   Current Tissue Engineered Heart Valve Approaches 
Two of the most recent advancements in the field have striven to incorporate the 
above concepts of tissue engineering into functional heart valves. The first concept, 
published by a group in China, is based on the fabrication of a hybrid heart valve leaflet. 
As has been stated before, the  formation  of  tissue-engineered heart valves can be 
distinguished by the scaffolding material- bioresorbable polymer scaffold, and  
decellularized heart valve scaffold  [173]. It has been shown that the bioresorbable 
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polymer scaffold cannot reproduce the functional complex three-dimensional composite   
heart valve leaflet architecture and has limitations in cellular  adhesion. And the  use  of  
a decellularized valve tissue matrix offers the advantages   of   its   innate   anatomical   
architecture and remaining biomechanical function. Therefore, they have striven to 
combine both approaches to form a hybrid biomatrix/polymer heart valve scaffold. The   
scaffold was fabricated from decellularized porcine aortic heart valve leaflet and coated  
with basic fibroblast growth factor (bFGF)/chitosan/poly-4-hydroxybutyrate (P4HB) 
using an electrospinning technique. Then, the hybrid heart valve leaflet was engineered   
by   seeding   mesenchymal stem cells (MSCs) onto the scaffold. Results showed that 
MSCs were present on the scaffolds and the electrospun  membrane firmly combined 
with the surface of the decellularized valve leaflets, concluding that the hybrid leaflets 
could be useful for heart valve tissue engineering. However, cellular infiltration into 
the scaffold has been limited, resulting in only surface population. 
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Figure 2.19: Valve-equivalent (VE) mold and fabrication. Cell-seeded fibrin-forming 
solution is injected into the complete mold (left). After gelation, the outer housing and 
plug are removed and mold and gel placed in culture medium. Culture for 3 weeks with 
gentle rocking results in a compacted bi-leaflet VE tissue (right).  
 
The next, and most recently published, by a team lead by Robert Tranquillo, is 
based on the entrapment of dermal fibroblasts into fibrin gel within a mold, which, 
following static incubation in the mold, yields the gross geometry and alignment patterns 
of the native aortic valve [174], as seen in the Figure 18 (above). 
The dermal fibroblast is used because it is a readily available source and generates 
extensive remodeling of fibrin into a collagenous tissue  with  tensile  mechanical  
properties  approaching  those  of native tissue [174]. Dermal fibroblasts have also been 
successfully used for a vascular graft in clinical studies [175]. The fibrin-based TEHVs 
are cast such that the tubular root and leaflets are a single entity. By using molds with two 
or three channels cut into the central mandrel, bi- and tri- leaflet VEs have been 
fabricated.  
In contrast to synthetic biodegradable polymers whose initial strength and 
stiffness values are greater than heart valve tissue, those of biological scaffolds like 
collagen or fibrin are orders of magnitude smaller. And, as stated earlier, realizing tissue 
growth to achieve physiological values of leaflet tensile and bending stiffness prior to 
implantation is crucial for their success. Shown by previous research with fibrin-based 
tubular constructs prepared with porcine aortic valve interstitial cells, it was illustrated 
that cyclic stretching with an incremental strain amplitude over three weeks can lead to at 
minimum an 84% greater ultimate tensile strength compared to statically-incubated  
controls,  which  correlates  with  increased  collagen deposition  and  maturation  [176]. 
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Therefore, Tranquillo’s team is developing a controlled stretch TEHV bioreactor  that can 
apply prescribed cyclic stretching to the VE root and leaflets during the entire  incubation  
(even  as  the  tissue  mechanical  properties change), while independently controlling the 
nutrient delivery (see Figure 2.20 below).  
It was concluded that using fibrin-based VEs prepared with human dermal 
fibroblasts, it is possible to create a TEHV with circumferential fiber alignment in the 
leaflet manifested as anisotropic stiffness comparable to native leaflets, a property that 
has not been achieved with TEHVs based on synthetic biodegradable polymers.  Though  
several  bioreactors  have  been  proposed  to mechanically condition TEHVs, they do not 
allow for controlled strain  to  be  applied  without  complicated  feedback  regulation, 
which has not been proposed. Using a strategy for controlled cyclic stretching of tubular 
constructs that they presented previously, they developed  a  controlled  cyclic  stretch  
bioreactor  for  TEHVs  that leads to improved tensile and compositional properties. 
Despite their exciting accomplishments, in vivo studies have been performed in the less 
mechanically demanding environment of the pulmonary valve position, where the valve 
is exposed to pressures far less than would be expected in the aortic position [177]. 
Furthermore, from preliminary data presented at the Heart Valve and Tissue Engineering 
meeting in Hilton Head (personal communication, March 2010), Dr. Tranquillo presented 
data that showed exstensive fibrosis after implantation, suggesting this scaffold may not 
be suitable for TEHVs.  
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Figure 2.20: (a) Schematic of controlled cyclic stretching TEHV bioreactor showing the 
reciprocating syringe pump for cyclic pressurization and stretching of the VE mounted 
within the latex tube, (b) image of the bioreactor with the latex housing slit to reveal the 
VE mounted within and its tie-down to both end pieces, and (c) end-on view of the VE 
through the glass window of the bioreactor during a stretching cycle, showing the leaflets 
coapting when the lumen is not pressurized, and separated when the lumen is pressurized 
and the root and leaflets are stretched [177].  
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3.1       Hypothesis 
Replacement or regeneration of heart valves, exquisite examples of 
hemodynamics, durability, design and adaptability has challenged engineers and surgeons 
for the last 40 years. Since about 300,000 diseased valves are replaced each year 
worldwide, this study is highly relevant to public health. Aortic heart valves are 
composed of three distinct layers: fibrosa, ventricularis and spongiosa. These layers are 
populated by interstitial cells which actively degrade and remodel the extracellular matrix 
to withstand billions of bending cycles without significant wear and tear. Tissue 
engineering, the emerging science of combining scaffolds, cells and specific mechanical 
and biochemical signals is feasible and holds great promise for treatment of heart valve 
disease [1]. Typical approaches include use of biodegradable polymers or decellularized 
porcine valves as scaffolds for in vitro cell seeding or in vivo cell infiltration and 
remodeling. Valves made by these procedures are either not strong enough to withstand 
aortic pressures or cannot be fully repopulated by cells. Recognizing the vital importance 
of the three leaflet layers [2], the outstanding hemodynamics of natural valve homografts 
[3] and the need for reconstruction of the physiologic valve design, we hypothesized that 
combination of four elements can be utilized for tissue engineering of the “ideal” aortic 
heart valve: A) Constructs made from partially stabilized collagenous scaffolds, B) 
Anatomically analogous 3-D heart valve shapes made from tri-layered structures that 
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mimic the native heart valve histo-architecture, C) Autologous multipotent mesenchymal 
stem cells for repopulation and remodeling and D) Mechanical cues to induce stem cell 
differentiation into valvular cells capable of maintaining matrix homeostasis.  
 
3.2       Specific Aims 
Aim 1: Preparation of engineered heart valve scaffolds 
Hypothesis: Functional heart valves can be created from layering of stabilized collagen 
scaffolds.  
Approach: Collagen layers to be used as fibrosa and ventricularis layers were prepared 
from decellularized pericardium and lightly cross-linked with penta-galloyl-glucose, a 
collagen binding polyphenolic tannin, to allow for delayed biodegradation. For the 
spongiosa layer, highly porous collagen scaffolds were prepared from decellularized, 
elastase-treated arteries and enriched with valve-specific glycosaminoglycans. 
Innovative features include unique engineering of tri-layered valvular structures from 
partially stabilized collagen scaffolds specifically designed to replace fibrosa, spongiosa 
and ventricularis.  
     
Aim 2: Adhering the three scaffolds used to form engineered heart valves 
Hypothesis: Functional heart valves can be created from layering of stabilized collagen 




Approach: To assemble the 3D heart valve structures from layers of collagen scaffolds, 
we developed and implemented use of biological adhesives in tissue engineering. After 
comparing several adhesives including cyanoacrylate, albumin, gelatin and fibrin-based 
glues, we chose to implement a modified albumin/glutaraldehyde adhesive for the 
construction of living heart valves and tested for mechanical properties and 
biocompatibility. 
Innovative features include unique use of a biological glue to assemble the tri-layered 
constructs, which has never been described before. 
 
Aim 3: Molding, assembly, and bioreactor testing of tri-layered scaffolds used for 
heart valve tissue engineering 
Hypothesis: Tissue engineered scaffolds that more closely mimic the 3D ultra-structure 
and  histo-architecture of a native aortic heart valve will functionally perform similar to a 
natural valve.  
Approach: Being aware of the vital importance of these layers, we assembled fibrous 
and spongy scaffolds in a three-layered structure based on anatomically accurate molds of 
aortic valves, in which the spongiosa layer is inserted between two purely collagen 
fibrous collagenous layer (fibrosa and ventricularis). Both gluing and layering techniques 
were used to create a fully-functional tri-layered construct. Layered collagenous 
constructs were tested for functionality in a custom-made bioreactor. 
 75 
Innovative features include unique use of molds to form the accurate shape and 
corrugations of each leaflet and the assembly of different scaffolds into a tri-layered 
construct. 
 
Aim 4: Differentiation of stem cells in tissue engineered heart valves into valvular 
interstitial-like cells  
Hypothesis: Stem cells exposed to 3D mechanical stimuli should share many similarities 
to natural valvular interstitial cells. These studies should indicate that physiologic 
mechanical stimuli offered by our 3D tissue engineered heart valve constructs and the 
heart bioreactor encouraged differentiation of stem cells into activated valvular interstitial 
cells, a much sought-after outcome of cardiovascular tissue engineering. We hypothesize 
that conditioning of stem cell-seeded engineered aortic heart valves in a bioreactor will 
induce cell differentiation.  
Approach: To  prove  that  relevant  mechanical  can  help  maturation  of  tissue 
engineered valves, we subjected stem cell-seeded constructs to in vitro cycling in a 
bioreactor that is similar to the intra-cardiac environment. We then evaluated cell 
differentiation.  
 Innovative features include the fact that remodeling behavior  of  stem  cells  seeded  





4.3       Clinical Significance and Translational Scenario 
Cardiovascular malformations are the most common congenital abnormality, 
affecting 4 to 6 in 1000 births, with valve defects accounting for up to 30% of these 
deficiencies [4, 5]. It is projected that by 2020 at least 1.4 million children will be 
affected [6]. A major problem associated with available valve replacements is that no 
existing replacements grow with the patient, which could mean a pediatric patient could 
need 2-4 valve replacements before 18 years old. Each of these surgeries is associated 
with a high operative mortality rate (10-36%) [7]. Furthermore, each operation on 
average could cost of a at least $54,000 (US average) [8], placing a large financial burden 
not only on the families of those affected but the entire health care industry in general. 
Therefore, tissue engineered heart valve replacements hold promise to solve this problem 
by creating a living heart valve that can grow with the patient. 
Our vision of a potential translational scenario using stabilized collagen scaffolds 
and autologous stem cells involves the following steps. After initial diagnosis and 
collection of mesenchymal stem cells from the patient, imaging of the diseased heart 
valve would provide anatomical coordinates for reconstruction of the heart valve 
geometry into solid molds using appropriate software and hardware. Minimizing size 
mismatch in implanted heart valve devices is an important aspect of heart valve surgery 
[1]. Concomitant with stem cell isolation, valves will be made from decellularized 
collagen scaffolds by assembly into tri-layered constructs and then cusps seeded with 
autologous stem cells as described in current study. After conditioning in bioreactors for 
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1-2 weeks for stem cell pre-differentiation into VIC-like cells, the patient-tailored 
engineered heart valve would be surgically implanted back into the patient. 
 
Figure 3.1: Translational scenario for tissue engineered heart valve. 
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4.1       Introduction 
Strategies for heart valve tissue engineering fall into two main categories [3]: a) 
preparation of decellularized heart valves by enzyme/detergent methods followed by 
repopulation with appropriate cell types in vitro before implantation or relying on host 
cells to repopulate and remodel the scaffolds in vivo. This approach has limitations, as 
complete valve decellularization was proven difficult to attain and cell repopulation is 
difficult due to lack of adequate porosity. A second approach is assembly of synthetic 
biodegradable matrices populated by cells and bioreactor conditioning to express 
adequate properties before implantation. While this approach seems appealing, the 
polymeric matrices lack sufficient mechanical strength and have not withstood the test of 
time under arterial pressure [3]. 
Therefore, a biologically-based scaffold may hold promise. Pericardium has been 
widely researched as a biomaterial, including examination of its mechanical and fiber 
orientation properties by mapping techniques [4], isolation of pericardial fibroblasts and 
analysis of their biosynthetic abilities [5,6] and detailed analysis of its collagen and 
proteoglycan components [5,6]. Glutaraldehyde (Glut) fixed bovine pericardium has a 
long history of being used in manufacturing of bioprosthetic heart valves, a good record 
of implantation in humans, is well characterized mechanically and biologically [1-4], has 
been used in development of collapsible percutaneous heart valves [10] and for mitral 
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valve repair [11]. Only recently has decellularized pericardium attracted attention as a 
scaffold for tissue engineering [9,12].  
Our working premise was that the ideal scaffolds for heart valve applications 
should be porous, strong, biocompatible, and conducive to cell repopulation and 
remodeling, while maintaining mechanical functions. Our novel strategy relies on use of 
stabilized collagen scaffolds that mimic the natural valve fibrous layers, based on 
decellularized porcine pericardium [5] and delicate, highly hydrated porous collagen 
scaffolds to be used as the middle spongiosa layer. We hypothesized that partially cross-
linked collagen scaffolds would fulfill these requirements. To test this hypothesis, 
collagen scaffolds were cross-linked with either ultraviolet (UV) light or penta-galloyl 
glucose (PGG) and then tested for biodegradation, mechanical properties and in vivo 
biocompatibility and remodeling. Their properties were compared to Glut-treated 
scaffolds. In the current study we demonstrate that PGG partially cross-links 
collagen and preserves the excellent mechanical properties of pericardium. PGG-
treated collagen scaffolds do not calcify in vivo and support progressive host cell 
infiltration and matrix remodeling, indicating that among the treatments tested, PGG is a 
most promising collagen stabilization process for heart valve tissue engineering.  
 
4.2       Materials and Methods 




PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium 
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(www.omnichem.be). Pure DNA, ribonuclease, glutaraldehyde (50% stock), and 
collagenase Type VII from Clostridium histolyticum, were purchased from Sigma-
Aldrich Corporation (St. Louis, MO). Deoxyribonuclease I was from Worthington 
Biochemical Corporation (Lakewood, NJ) and Bicinchoninic acid protein assay kits from 
Pierce Biotech (Rockford, IL). Electrophoresis apparatus, chemicals and molecular 
weight standards were from Bio-Rad, Hercules, CA and elastase was from Elastin 
Products Company, Owensville, MO. All other chemicals were of highest purity 
available and typically obtained from Sigma Aldrich, St. Louis, MO.    
 
4.2.2    Methods 
4.2.2.1 Spongy Scaffold Preparation 
For preparation of spongiosa scaffolds, porcine pulmonary arteries obtained from 
Animal Technologies Inc. (Tyler, TX) were decellularized. In the first step, tissues were 
stored in double distilled water overnight at 4
o
C to induce hypotonic shock and cell lysis. 
After rinsing, tissues were treated with 0.25% Na-Deoxycholate, 0.15% Triton X-100, 
0.1% EDTA, 0.02 % NaN3, in 50 mM Tris-HCl buffer (pH 7.8) with mild agitation for 
six days at 22ºC, and changes of the solution after three days. After rinsing with double-
distilled water and 70% ethanol to remove detergents, tissues were treated with a 
deoxyribonuclease / ribonuclease mixture (360 milliunits/ml for each enzyme) at 37ºC for 
24 hours to fully digest away nucleic acids. This was followed by rinsing twice with 
double distilled water and incubation in ultra pure elastase (10 Units/ml) in 50 mM Tris 
buffer, 1 mM CaCl2, 0.02% NaN3  (pH=8), at 37
o
C for six days with mild agitation. 
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Elastase was replaced with fresh solution after three days. Tissues were rinsed in double 
distilled water at 22ºC until Bicinchoninic acid protein assay revealed undetectable levels 
of soluble proteins. Scaffolds were finally rinsed with 70% ethanol and then stored in 




4.2.2.2 Spongy Scaffold characterization 
For histology, paraffin-embedded samples were stained with Hematoxylin and 
Eosin (H&E) and Masson’s trichrome (n=6 slides per group per stain). To detect Gal we 
performed lectin histochemistry using biotinylated Griffonia simplicifolia lectin as the 
primary reactant, followed by ABC-peroxidase complex and DAB detection with 
Hematoxylin counterstaining [6]. Scanning electron microscopy (SEM) sample 
preparation was performed according to standard procedures [7] and imaged on a Hitachi 
S4800. To test for cytocompatibility, rat dermal fibroblasts were seeded (10
5
 cells per 
cm
2
) onto sterile scaffolds and cell viability and proliferation evaluated weekly for up to 
5 weeks using LIVE/DEAD
®
 stain (Molecular Probes, Carlsbad, CA) and CellTiter 96
®
 
AQueous One Solution Cell Proliferation Assay MTS (Promega, Madison, Wisconsin) as 
per manufacturers’ directions. Samples were also stained with 4-6 Diamidino-2-
phenylindole (DAPI) blue fluorescent nuclear stain.  
Total genomic DNA was extracted and purified from scaffolds and from fresh 
arteries as controls (n = 3 per group), using a Fibrous Tissue DNeasy Kit (Qiagen, 
Valencia, CA), subjected to agarose/ethidium bromide gel electrophoresis followed by 
densitometry using Gel-Pro Analysis Software (MediaCybernetics, Silver Spring, MD). 
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Water content was calculated gravimetrically from weights obtained before and after 
freeze-drying of fresh artery and scaffold samples (n = 6 per group). Glycosaminoglycan 
(GAG) content was analyzed by full digestion of fresh tissue and scaffolds with protease 
K followed by reaction of released GAGs with 1,9-dimethylmethylene blue dye and 
colorimetry [8, 9]. 
 
 
4.2.2.3 Fibrous Scaffold preparation 
Fresh adult swine pericardial sacs obtained from Animal Technologies Inc. 
(Tyler, TX) were cleaned, rinsed in sterile saline, cut into strips, and then decellularized 
as follows. In the first step, tissues were stored in double distilled water overnight at 4
o
C 
to induce hypotonic shock and cell lysis. After rinsing, tissues were treated with 0.25% 
Na-Deoxycholate, 0.15% Triton X-100, 0.1% EDTA, 0.02 % NaN3, in 50 mM Tris-HCl 
buffer (pH 7.8) with mild agitation for six days at 22ºC, and changes of the solution after 
three days. After rinsing with double-distilled water and 70% ethanol to remove 
detergents, tissues were treated with a deoxyribonuclease / ribonuclease mixture (360 
milliunits/ml for each enzyme) at 37ºC for 24 hours to fully digest away nucleic acids. 
This was followed by rinsing twice with double distilled water and incubation in ultra 
pure elastase (10 Units/ml) in 50 mM Tris buffer, 1 mM CaCl2, 0.02% NaN3  (pH=8), at 
37
o
C for six days with mild agitation. Elastase was replaced with fresh solution after 
three days. Tissues were rinsed in double distilled water at 22ºC until Bicinchoninic acid 
protein assay revealed undetectable levels of soluble proteins. Scaffolds were finally 
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4.2.2.4 Fibrous Scaffold characterization 
For histological evaluation, paraffin-embedded samples were stained with 
Hematoxylin and Eosin for general morphology and confirmation of cell removal and 
with Verhoeff van Gieson to confirm removal of elastin (n=6 slides per group per stain). 
Digital pictures were taken of Hematoxylin and Eosin stained samples (n=2 slides per 
group) at 400X magnification and open spaces (pores) between intact collagen fibers 
were measured using AxioVision Release 4.6.3 digital imaging software (Carl Zeiss 
MicroImaging, Inc. Thornwood, NY). To further validate decellularization, total genomic 
DNA was extracted and purified from collagen scaffolds and from fresh pericardium as 
controls (n=3 per group), using a Fibrous Tissue DNeasy Kit (Qiagen, Valencia, CA) 
following manufacturers’ instructions. DNA samples were subjected to agarose 
electrophoresis alongside pure DNA standards (10-100 ug/ml) followed by densitometry 
using Gel-Pro Analysis Software (MediaCybernetics, Silver Spring, MD). DNA levels 
were calculated from the standard curve and normalized to initial tissue wet weight. To 
detect Gal we performed lectin histochemistry using biotinylated Griffonia simplicifolia 
lectin as the primary reactant, followed by ABC-peroxidase complex and DAB detection 
with Hematoxylin counterstaining [6]. 
To test for presence of soluble proteins, scaffolds and fresh pericardial samples 
(n=2 per group) were pulverized in liquid N2, proteins extracted in an extraction buffer 
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(50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% Sodium 
Deoxycholate, 0.1% SDS, pH 7.4, with protease inhibitor cocktail) and protein content 
determined using BCA assay. Samples normalized to initial dry weight were analyzed for 
detergent-soluble proteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
followed by silver staining (SilverSnap, Pierce Biotech, Rockford, IL). For detection of 
matrix metalloproteinase 2 (MMP-2) same protein extracts were analyzed by an MMP-2 
ELISA kit (Amersham Biosciences, Piscataway, NJ) and results normalized to mg 
soluble protein.  
Chemotaxis assays were conducted using a Boyden chamber (NeuroProbe, 
Gaithersburg, MD) and a polycarbonate filter with 8 µm diameter pores, as per 
manufacturers’ instructions. Soluble collagen peptides (matrikines) were prepared by 
treatment of decellularized porcine pericardium with collagenase (10 U/ml) for 24 hours. 
The supernatant was filtered through Microcon YM-3 centrifugal devices and peptides 
smaller than 3 kDa were collected in the flow-through for chemotaxis assays. Rat aortic 
fibroblasts (10x105/well, prepared in house by an explant technique) suspended in 
DMEM/0.1% bovine serum albumin were used in these tests; undiluted Fetal Bovine 
Serum (100%) was used as a positive control and DMEM/0.1% bovine serum albumin as 
the negative control. Cells migrated for 4 hours at 37ºC and 5% CO2. After incubation, 
the non migrated cells were removed with a wiper blade and the filter fixed and stained 
using a DiffQuick® kit (Dade Behring Inc, Newark, DE) dried, and screened for 
migrated cells using an inverted microscope. Results were reported as negative (0-2 cells 
per 10x field), slightly positive (2-10 cells), or positive (> 10 cells).       
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4.2.2.5 Evaluation of PGG cross-linking and stability 
To evaluate the cross-linking efficiency of PGG, fibrous scaffolds were treated 
with different concentrations of PGG (0%, 0.1%, 0.15%, and 0.3%) and leaching of PGG 
was tested. Briefly, ½” diameter circles of decellularized pericardium were cut using a 
core borer. The circles were then placed in PBS. For a long wash procedure, the circles 
were next placed in corresponding PGG concentrations for fixation (for 24 hrs.). The 
circles were then removed from PGG after 24 hrs., and placed in sterile PBS w/ 0.02% 
azide (making sure to keep groups separated) and shaken on an oscillating shaker at room 
temp. The wash was removed and replaced with new PBS every day for 5 days. At the 
end of the long wash procedure, circles designated for a short wash were placed in 
corresponding concentrations of PGG (as for long wash). All circles were then washed 
2X in sterile PBS by gentle inversion, then place circles in 70% ethanol for 10 mins. in 
sterile 50 ml conical tube.. The circles were then washed 2x in sterile PBS by gentle 
inversion in sterile 50 ml conical tube.  The circles, keeping differing concentrations of 
PGG-fixed circles separated, were placed in 50/50 FBS/DMEM (in sterile 50 ml conical 
tubes) for 24 hrs in an incubator at 37°. The disks were then removed  from 50/50 tubes 
and placed in new tubes with glycine for ~2hrs. The disks were then removed from 
glycine and each disk placed in a well of a 12-well plate (NOT tissue culture treated). 
Approximately 50,000 rat aortic fibroblasts were placed directly to top of each circle. The 
plate was placed in an incubator @ 37° for 2 hrs. Live/Dead and MTS assays were then 
preformed on the samples. 
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Next, fibrous scaffolds were treated with different concentrations of PGG  (0%, 
0.0375%, 0.075%, 0.10%, and 0.15%, n=6 per concentration) and exposed to collagenase 
to test degradation properties. The long wash procedure was followed as above. At the 
end of the washes, the circles were then placed in collagenase (as described in section 
4.2.3.5) for 7 days. 
 
4.2.2.6 Properties of cross-linked fibrous collagen scaffolds  
Scaffolds were prepared as above and treated with one of three methods: (a) 
Glutaraldehyde (Glut), (b) Penta-galloyl-glucose (PGG), and (c) Ultraviolet light (UV) ,. 
For UV treatment, scaffold samples were first dried flat in sterile conditions (2 days in a 
cell culture hood at 22ºC), then UV-treated in a Spectrolinker XL-1000 UV cross linker 
(Spectronics Corporation, Westbury, NY) at optimal density (1200 x 100 µJ/cm2) for 30 
minutes. Samples were stored dry at 4oC until use. For Glut fixation, wet scaffold 
samples were incubated in 0.6% glutaraldehyde in 50 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffered saline (pH=7.4) overnight at 22ºC and 
subsequently rinsed and stored in sterile saline. For PGG fixation, the scaffolds were 
incubated with 0.15% PGG in 50 mM phosphate buffer (pH 5.5) containing 4% 
isopropanol, for 24 hours at 22oC, rinsed and stored in sterile saline.  
To evaluate cross-linking efficacy, scaffold samples were tested for resistance to 
collagenase. Treated and untreated samples (n=18 per group) of about 15 x 5 mm were 
rinsed 3 times in ddH20 at 22ºC and lyophilized to record dry weight. Each sample was 
then incubated separately with 1 ml of collagenase (6.25 units/ml) dissolved in 100 mM 
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Tris buffer, 1 mM CaCl2, 0.02% NaN3 (pH=7.8) for 1, 2, and 7 days at 37ºC with mild 
agitation. At each time point, 6 samples from each group were rinsed 4 times with ddH20 
by centrifugation (12,000 rpm, 1.5 minutes, 18ºC) after which the samples were 
lyophilized to obtain dry weights after collagenase, and percent of digested tissue was 
calculated. 
Three specimens from each group of (1) control (no fixation), (2) Glut, (3) PGG-
treated scaffolds, and (4) UV were also subjected to thermal denaturation temperature 
(Td) analysis by Differential Scanning Calorimetry (DSC-131, Setaram Instrumentation, 
Caluire, France). Specimens were tested at a heating rate of 10˚C/min from 20˚C to 
110˚C in a N2 gas environment. Td, a well known indicator of collagen cross-linking was 
defined as the temperature at the endothermic peak [13].  
 
4.2.2.7 In vivo evaluation of fibrous scaffolds 
Male, juvenile Sprague-Dawley rats (weighing around 50 grams, from Harlan 
Laboratories; Indianapolis, IN) were sedated with acepromazine (0.5 mg/kg, Ayerst 
Laboratories, Rouse Point, NJ) and maintained on 2% isoflurane during surgery. A small 
transverse incision was made on the backs of the rats and two subdermal pouches (one 
superior and one inferior to the incision) were created. Samples were prepared for 
implantation by overnight soaking in sterile saline. Controls (no cross-linking), Glut-
treated, PGG-treated, and UV-treated scaffold samples (as prepared above) were 
implanted into the subdermal pouches (n=8 implants per group per time point) and 
incisions closed with surgical staples. After surgery the rats were allowed to recover and 
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permitted free access to water and food. The animal protocol was approved by the 
Animal Research Committee at Clemson University and NIH guidelines for the care and 
use of laboratory animals (NIH publication #86-23 Rev. 1996) were observed throughout 
the experiment. 
The rats were humanely euthanized by CO2 asphyxiation at 1, 3, and 6 weeks 
after surgery and samples retrieved for analysis. A small section of each explant with its 
associated capsule was maintained for histological evaluation. The remainder of explants 
were cleaned free of capsule rinsed in saline and then divided for DNA, calcium and 
matrix metalloproteinase (MMP) analysis.  
For histology samples were placed in formalin and paraffin sections (5 µm) were 
stained with Hematoxylin and Eosin \ for general morphology. For identification of 
infiltrating cell types, samples tagged for immunohistochemistry  were placed in formalin 
[17,18] and paraffin-embedded. Sections (5 µm) were exposed to 0.1% Proteinase K 
solution (25 units/500 ml, from Qiagen DNeasy Tissue Kit) in Tris Buffer Saline (TBS), 
pH=7.5 at 22ºC for 30 seconds. Endogenous peroxidases were blocked with 0.3% H2O2 
in 0.3% normal sera (Vectastain Elite ABC kit for rabbit IgG, Burlingame, CA). Sections 
were immunostained using mouse anti-rat monoclonal antibodies to macrophages (1:200 
dilution, Chemicon, Temecula, CA), vimentin (1:500 dilution, Sigma, St. Louis, MO) and 
Prolyl-4-hydroxylase (1:200 dilution, Chemicon, Temecula, CA) at 22ºC for 1 hour. To 
minimize cross reactivity, rat-absorbed biotinylated anti-mouse IgG was used in place of 
biotinylated secondary antibody provided with the staining kit. Negative staining controls 
were performed with the omission of the primary antibody. Diaminobenzidine 
 90 
tetrahydrochloride peroxidase substrate kit was used to visualize the specific staining 
(Vector Laboratories, Burlingame, CA) and sections were lightly counter-stained with 
Hematoxylin. As positive controls we stained paraffin sections from rat spleen 
(macrophage control) and rat skin (fibroblast control) in parallel with the explant 
sections.  
To visualize phenol groups within PGG-treated samples we used an iron-based 
histology stain [19] [10][10][9][12][12]. Briefly, tissues were stained en-bloc with FeCl3, 
embedded in Tissue Tek OCT compound (Sakura Finetek, USA Inc., Torrance, CA) and 
six micrometer thick sections counterstained with Light green. PGG appears brown with 
this staining.  
For DNA analysis explants (n=3 per group per time point) were weighed and then 
subjected to DNA extraction and purification using the Qiagen Kit and DNA content 
evaluated by agarose gel electrophoresis followed by densitometry as described above.    
Explanted samples (n=4 per group per time point) were rinsed in saline, lyophilized to 
obtain dry weight and individually hydrolyzed in 6N HCl, dried under nitrogen, and 
reconstituted in 1.0 ml of 0.01 N HCl. Calcium content was then measured using atomic 
absorption spectrophotometry as described before [20,21]. 
For matrix metalloproteinase detection, proteins were extracted in 50 mM Tris, 
1% Triton X-100, 0.1% SDS, 1% Deoxycholate, 150 mM NaCl, with protease inhibitor 
mixture, pH=7.4 buffer and protein content determined using the Bicinchoninic acid 
assay as described before [19]. Samples were subjected to gelatin zymography using 6 µg 
of protein per lane alongside molecular weight standards [22]. Intensity of MMP bands 
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(white bands on dark background) were evaluated by densitometry using Gel-Pro 
Analysis Software (MediaCybernetics, Silver Spring, MD) and expressed as relative 
density units (RDU) normalized to protein content. 
Glycosaminoglycan content in explanted tissues was determined by a 
dimethylmethylene blue assay as described before [13]. Briefly, a sample of extracted 
protein (described above for MMP assay) was digested with papain and released 
glycosaminoglycans were incubated with dimethylmethylene blue reagent and OD read at 
525nm. Glycosaminoglycan content was calculated from a standard curve of pure 
chondroitin sulfate (0-25 ug/ml) and values expressed as µg/mg protein.  
 
Statistics   
Results are represented as means ± the standard error of the mean (SEM). Statistical 
analysis was performed with one way Analysis Of Variances (ANOVA) and results were 
considered significantly different at p<0.05.  
 
4.3       Results 
4.3.1    Scaffold Characterization 
4.3.1.1 Spongy Scaffold characterization 
Highly hydrated, collagen scaffolds to be used as valvular spongiosa were 
prepared from porcine pulmonary aorta by decellularization and removal of elastin. 
Histology showed complete cell and elastin removal from the pulmonary aorta (Figure 
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4.1), leaving behind a porous collagen scaffold with pore sizes ranging between 20 and 
100 microns. 
 
Figure 4.1: Histology of spongy collagen scaffolds. (A, C) fresh porcine pulmonary 
artery and (B, D) decellularized pulmonary artery scaffolds were stained with H&E stain 
(A, B), Trichrome stain (C, D, collagen blue, cells dark pink).  
 




Figure 4.2: Histology of spongy collagen scaffolds.  (A) fresh porcine pulmonary artery 
and (B) decellularized pulmonary artery scaffolds stained with GS lectin for Gal antigen 
(A & B, dark brown = positive staining). Bars are 50 m. 
 
Analysis of spongiosa scaffold by contrast phase microscopy and SEM revealed a 
3-D matrix composed of insoluble collagen fibrils of 1-2 microns in diameter assembled 
into larger fibers and wavy bundles.  
 
Figure 4.3: Properties of spongiosa scaffolds. (A,B) Phase contrast micrographs of  fresh  
scaffolds. Bars are 100 m  
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Figure 4.4:  Properties of spongiosa scaffolds. (A) SEM image of scaffold surface.  
 
The spongy scaffold was fully degradable by collagenase in vitro (not shown) and 
supported fibroblast growth and proliferation for up to 5 weeks (Figure 4.5).  
 
Figure 4.5: Properties of spongiosa scaffolds. (A, B)  Cytocompatibility  testing  with  
fibroblasts  stained  with  Live/Dead stains  (live  cells  green,  dead  cells  red)  and  
DAPI  nuclear  stain  (light  blue),  respectively. Bars are 100 m.  
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Semi quantitative DNA analysis revealed almost complete cell removal. 
Specifically, levels of high molecular weight genomic DNA were significantly reduced 
and there was no sign of morphologically identifiable cells by histology, thus we 
considered the scaffolds acellular. As can be seen on the agarose gels (Figure 4.6), 
minute amounts of low molecular weight DNA fragments may have been trapped in the 
scaffolds but we did not consider this a sign of cell presence. 
 Macroscopically, spongiosa collagen scaffolds appeared as white, highly 
hydrated matrices which, when compared to the native tissue, occupied almost 4 times 
larger volumes than the original artery while maintaining the original shape and more 
than 90% water (Figure 4.7).  
 
Figure 4.6: Properties of spongiosa scaffolds. (A) Shows agarose/Ethidium bromide 
electrophoresis, of  extracted  DNA,  alongside  pure  DNA  standard while (B) quantifies 
DNA content of fresh and decellularized scaffolds  
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Figure 4.7: Properties of spongiosa scaffolds. Water  content  of  fresh  and  
decellularized scaffolds;  insert  shows  macroscopic  aspects  of  10  x  10  mm  arterial  
tissue  samples  before  (left)  and after (right) decellularization/elastase treatment.  
 
Glycosaminoglycans (GAGs) were also analyzed in tissues and scaffolds. As 
compared to fresh pulmonary artery (14.6 ug GAGs/mg dry), the spongiosa layer 
contained about 8.5 ug GAGs/mg dry, which is about 3 times lower than values reported 
in the literature for the whole aortic cusp (25 ug GAGs/mg dry). To date we have no 
knowledge of precise GAG content of the spongiosa layer alone in native aortic heart 
valves.      
 
4.3.1.2 Fibrous Scaffold Characterization 
Our technique for decellularizing porcine pericardium involved hypotonic shock, 
detergent extractions, nuclease digestions and elastase treatment. Results showed that an 
acellular structure of histologically intact pure wavy collagen fibers with long inter-fibril 
open spaces (pores) of 8-30 microns in diameter was obtained (Figure 4.8 (A-D)).   
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Figure 4.8: Histology of fibrous scaffolds. (A) H&E staining of acellular scaffold 
showing wavy collagen fibers interspersed with pores. Note complete lack of cell 
staining, as compared to native tissue (B) where cells are outlined by black arrows. (C) 
VVG staining showed fine elastin fibers (black arrow) throughout the native pericardial 
tissue, which were completely removed (D) by elastase treatment 
 
 
Figure 4.9: Histology of spongy collagen scaffolds.  (A) fresh porcine pericardium, and 
(B) decellularized pericardium scaffolds stained with GS  lectin for Gal antigen (A & B, 
dark brown= positive staining). Bars are 50 m.  
 
Histochemical staining showed the fibrous scaffold lacked Galα antigen. 
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The large majority of the fibers were insoluble since strong detergent extractions 
yielded very few extractable proteins as evidenced by electrophoresis and silver-staining 
(Figure 4.10).  
 
Figure 4.10: Properties of fibrous scaffolds. Presence of SDS-soluble proteins in fresh 
pericardium and acellular collagen scaffolds was evaluated by SDSPAGE and silver 
staining 
 
Decellularization was confirmed by DNA extraction and evaluation using agarose 
gel electrophoresis (Figure 4.11 (A)) followed by densitometry (Figure 4.11 (B)), which 
showed more than 94% reduction in DNA content.  
Furthermore, histochemical staining showed that both the fibrous scaffold 
(derived from pericardium) as well as the spongiosa scaffold lacked Galα antigen. 
ELISA measurements showed significantly lower levels of remnant MMP-2 activity in 
scaffolds as compared to fresh pericardium (Figure 4.12).  
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Figure 4.11: Properties of fibrous scaffolds. (A) Agarose/ethidium bromide gel 
electrophoresis of DNA extracted from fresh pericardium and the acellular collagen 
scaffolds; (B) densitometry of DNA bands in (A) 
 
                                        
 
Figure 4.12: Properties of fibrous scaffolds. ELISA for MMP-2 in fresh pericardium and 
the acellular collagen scaffolds. 
 100 
Fibroblasts exhibited a strong positive chemotaxis toward collagen peptides obtained 
from decellularized pericardium (Figure 4.13) suggesting that scaffold degradation 
products could encourage repopulation by acting as matrikines.  
                   
 
Figure 4.13: Characteristics of acellular porcine collagen scaffolds: Chemotaxis of 
fibroblasts towards collagen peptides obtained from acellular pericardium; inset in (A) 
shows a cell undergoing mitosis after chemotaxis, (B) positive chemotaxis control, (C) 
negative control.           
 
4.3.1.3 Evaluation of PGG cross-linking and stability 
 To evaluate the cross-linking efficiency of PGG, fibrous scaffolds were treated 
with different concentrations of PGG (  0%, 0.1%, 0 .15%, and 0 .3%) and leaching of 
PGG was tested. There was no significant difference in cell viability between the 3 
concentrations tested as given by MTS assays (Table 4.1) 
 101 
                
Table  4.1  
 
 
However, there is a noticeable difference in the cell viability on each of the scaffolds 
when the Live/Dead assay was used, with the 0.15% scaffold being the highest 
concentration with viable cells. The 0.3%-fixed scaffold showed no live cells upon 
evaluation (Live/Dead shown for 0.15%-treated scaffold).  
  
 
Figure  4.14: Phase contrast (A) and Live/Dead (B) of 0.15%-fixed scaffold that was 




Figure   4.15: Collagenase study with scaffolds washed for a week. 
 
The PGG, fibrous scaffolds were then treated with different concentrations of PGG  (0%, 
0.0375%, 0.075%, 0.10%, and 0.15%) based on leaching studies above and washed over 
a one week time, then exposed to collagenase to test degradation properties.  
Results showed there was a significant difference between 0.10% and 0.15% 
PGG-fixation and all other concentrations, as well as there is a significant difference 
between 0.10% and 0.15%, therefore the 0.10% and 0.15% concentrations prevent 
degradation of the scaffold more effectively than the other concentrations. 
 
4.3.1.4 Properties of cross-linked fibrous collagen scaffolds  
Collagen scaffolds were treated with Glut, a known protein cross linker [11], 
PGG, a compound known to interact with Proline-rich proteins such as collagen [12], and 
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UV-light. Samples were then tested in vitro for resistance to collagenase, mechanical 
properties and thermal denaturation characteristics. Collagenase was used as an 
accelerated model for degradation and a widely accepted test that reveals extent of 
collagen cross-linking [13, 14]. Results showed that control, untreated scaffolds were 
almost completely digested by collagenase in 1-2 days (Figure 4.16), suggesting that 
decellularized porcine pericardium is highly biodegradable.  
    
Figure 4.16: Resistance to collagenase of treated collagen scaffolds; a time-course study. 
Percent mass loss after collagenase treatment is shown for untreated scaffolds (control) 
and for UV, Glut and PGG-treated scaffolds. Control values were all significantly higher 
than other groups. *ANOVA statistical significance between groups. 
 
Expectedly, Glut-treated collagen was highly resistant to collagenase at all time points, 
indicating that glutaraldehyde fixation of collagen is very strong and practically 
irreversible. PGG-treated collagen scaffolds exhibited excellent resistance to collagenase 
at 1 and 2 days with a slight but significant (p<0.05) increase in mass loss at 7 days 
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(almost 15% degradation by collagenase). These data suggest that PGG and UV 
treatment are good short-term collagen fixatives. 
Differential scanning calorimetry analysis showed Td values of 76.9±1.0oC 
(mean ±SEM) for control scaffolds, 86.9±0.2oC for Glut and 78.2±0.6oC for PGG-
treated scaffolds. All values were statistically different among groups (ANOVA, p<0.05), 
with the exception of PGG vs. control (p=0.454).  
 
4.3.1.5 In vivo biocompatibility studies of fibrous scaffolds 
To study biocompatibility and cell repopulation potential of our scaffolds we 
implanted samples subdermally in juvenile rats and analyzed them at 1, 3, and 6 weeks 
post-implantation. H&E staining (Figure 4.17) revealed a time dependent increase in cell 
infiltration in control (untreated) scaffolds associated with visible collagen fiber 
degeneration, confirming the fact that the collagen scaffold is degradable in vivo. Glut-
fixed collagen scaffolds showed good collagen fiber preservation and significantly less 
cell infiltration (Figure 4.17 (C)) validating the fact that Glut-treated collagen is not an 
ideal substrate for cell-mediated remodeling.  
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Figure 4.17:  Histological analysis of subdermally implanted scaffolds. Representative 
H&E micrographs from 3 weeks samples showing (A) pre-implant collagen scaffolds, 
(B) explanted control scaffolds, (C) explanted Glut-treated scaffolds, and (D) explanted 
PGG-treated scaffolds. Black arrows point to cells present within implants.  
 
PGG-treated scaffolds (Figure 4.17 (D)) exhibited clear signs of collagen fiber 
degradation, visibly less than control untreated collagen and more than Glut-fixed 
collagen. Similarly, larger numbers of infiltrating cells were found in PGG-treated 
collagen as compared to Glut-fixed collagen, but less than in untreated controls. Cell 
infiltration in PGG treated scaffolds increased with time, clearly showing that PGG 
treatment is not cytotoxic. UV-treated scaffolds exhibited a dramatically collapsed 
structure, practically impenetrable to cells at all time points (Figure 4.18).  
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Figure 4.18:  Histological analysis of subdermally implanted scaffolds. Representative 
H&E micrographs from 3 weeks samples showing UV-treated scaffold before (A) and 
after implantation (B). Black arrows point to cells present within implants. 
 
Histology data was confirmed by quantitative DNA analysis. Despite considerable 
biological variability among samples, data showed significant DNA present at all time 
points in most tissues, with less DNA present in Glut-fixed tissues at 3 weeks (p<0.05). 
Comparative analysis of 6 week vs. 3 week data revealed that DNA content apparently 
reached a plateau after 3 weeks, indicating that cell infiltration is complete within this 







DNA levels in explanted collagen scaffolds 
Samples DNA content (g / gram wet weight ± SEM, n=3) 
 1 week 3 weeks 6 weeks 
Control    910 ± 130
b
 1459 ± 185   961 ± 373 
UV 1108 ± 145        3258 ± 1102
a, b
 2179 ± 488 
Glut 1121 ± 318      578 ± 21
a, b
 1396 ± 341 




statistical significance among time points within each fixation group (p<0.05). 
b  
statistical significance among groups at each time point (p<0.05). 
Table  4.2 
  
A large majority of cells infiltrating collagen scaffolds were vimentin-positive 
cells resembling fibroblasts (Figure 4.19 (A)). Cell density apparently increased with 
time of implantation for control and PGG scaffolds, while cell infiltration in Glut-fixed 
scaffolds was significantly reduced at all time points. Infiltrating cells were also positive 
for proline-hydroxylase, an enzyme involved in collagen synthesis (Figure 4.19 (B)). 








Figure 4.19: Immunohistochemical identification of infiltrating cells. a) Vimentin stain 
showing extensive fibroblast-like infiltrating cells in all implant groups at 1 week (1w), 3 
weeks (3w) and 6 weeks (6w) after implantation. b) Proline-hydroxylase 
immunohistochemical staining; arrowheads point to positively stained cells. c) Specific 
staining showing very few macrophages (arrowheads). Inset in (c) shows macrophage 
staining of rat spleen sections used as a positive control. Sections were counterstained 
with hematoxylin (nuclei dark blue). Bars are 50 microns in all micrographs. 
 
Calcium analysis in explanted scaffolds (Table 4.3) revealed significantly high 
levels in Glut-fixed and UV-treated collagen while control, untreated collagen scaffold 
samples, as well as PGG-treated scaffolds did not accumulate any significant amounts of 
calcium, indicating that despite effective collagen stabilization, PGG treatment may not 
induce collagen calcification while UV treatment induces significant calcification of the 
scaffolds.  
 
Calcium levels in explanted collagen scaffolds 
Samples Ca content (g / mg dry weight ± SEM, n=4 ) 
 1 week 3 weeks 6 weeks 
Control 1.4 ± 0.5 1.2 ± 0.3   0.5 ± 0.1 
UV   32.6 ± 17.5
b
   97.3 ± 17.2
a, b
     121.9 ± 11.7
a, b
 
Glut 2.8 ± 1.4  5.4 ± 3.8   4.6 ± 2.6 
PGG 1.4 ± 0.4 1.5 ± 0.5   1.1 ± 0.2 
a  
statistical significance among time points within each fixation group (p<0.05).          
b  








Phenol staining showed tight binding of PGG to collagen (Figure 4.20 (A)) which 
appeared to be maintained even after 3 weeks of subdermal implantation (Figure 
4.20(B)) suggestive of stable PGG-collagen interactions.  
 
 
Figure 4.20: Histological analysis of subdermally implanted scaffolds. (A) Phenol 
staining showing collagen-bound PGG (brown) before implantation and (B) 3 weeks after 
subdermal implantation. Insert in (A) represents phenol staining of a negative control 
(scaffold not treated with PGG).   
 
Matrix metalloproteinase (MMP) activity was measured in explants from all time 
points using gelatin zymography (Figure 21). Two major proteases were identified in 
tissue extracts, namely MMP-9 (migrating at around 90-95 kDa) and MMP-2 (65-80 
kDa). Band intensity was measured for each sample (normalized to protein content) and 
represented as relative density units or RDU (Figure 21). Similar trends were observed 
for MMP-9 and MMP-2, i.e. high enzyme levels at 1 and 3 weeks, leveling off at 6 
weeks. Activity of MMP-2 was about 10 times higher in all samples as compared to 
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MMP-9. The total MMP enzyme activity distribution resembled that of the DNA content. 
In addition, glycosaminoglycan levels within all implant groups showed a mean overall 
value of 175 +/- 30 ug per mg extracted protein, but without showing statistical 
significance among treatment groups and time points (p>0.05). Overall results suggest 
the presence of cells actively involved in matrix remodeling.  
 
Figure 4.21: MMP activities in explanted scaffolds. Densitometry of active MMP bands 
are expressed as relative density units (RDU) normalized to protein content. MMP-9 (A) 
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and MMP-2 (B) were identified from their relative migration on gelatin containing 10% 
polyacrylamide gels (insets show representative zymograms).    
 
4.4       Discussion 
It is our premise that the outstanding performance of allografts is mainly due to 
the fact that they very closely mimic the natural valve anatomy. Since collagen represents 
the predominant component of heart valves we hypothesized that use of collagen 
membranes engineered to mimic the native anatomical heart valve structure would serve 
as an effective approach to heart valve tissue engineering.  
It is vital that implanted heart valves function immediately after implantation but 
also support host cell infiltration and remodeling. It is our working hypothesis that such 
properties can be achieved by development of partially cross-linked collagen scaffolds. 
Full cross-linking would reduce cell infiltration and remodeling capacity to a minimum 
and thus may prevent tissue regeneration. Conversely, uncross-linked scaffolds may 
degrade too rapidly after implantation and thus reduce functionality of the tissue 
engineered heart valves. Moderately cross-linked scaffolds would allow for slow but 
sustained cell infiltration with temperate remodeling of the scaffold, without alterations in 
valve properties. In current study we evaluated non-Glut fixation methods such as UV 
light and PGG treatments of acellular porcine pericardium for development of novel 
scaffolds for heart valve tissue engineering.            
In current study we illustrated development of a new scaffold to be used as a 
spongiosa layer for heart valve tissue engineering. The middle spongiosa layer, 
composed primarily of glycosaminoglycans (GAGs) and collagen, is easily deformed in 
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the presence of shear forces and cushions shock during the valve cycle and is not readily 
compressed. This resistance to compression during bending aids in cuspal mechanics by 
preventing buckling during flexion (systole), which could result in overall cuspal damage 
[15]. To obtain pure collagen scaffolds with constant and predictable composition and 
properties, porcine pulmonary artery was successfully decellularized using hypotonic 
shock, detergent extraction and  nuclease  digestion. The scaffold was further treated with 
elastase. Removal of elastin created supplementary pores for cell infiltration and assisted 
with tissue decellularization. The spongiosa has a gelatinous consistency, due in large 
part to the hydrophillicity of the GAG molecules. This novel acellular scaffold composed 
of collagen and GAGs was highly hydrated, porous and hydrophilic, showed good 
preservation of matrix components, lacked Galα antigens and supported in vitro cell 
repopulation. Enhanced scaffold characterization could be obtained by more extensive 
ultra structural analysis of collagen and elastin fiber integrity, GAG components and 
presence of minute cell debris [16, 17].  
Porcine pericardium was successfully decellularized using hypotonic shock, 
detergent extraction and nuclease digestion. This is an accepted decellularization 
approach for fibrous connective tissues [29]. Since pericardium contains about 10% 
elastin, we added an extra step, elastase treatment, to fully remove elastin, increase 
porosity and make mechanical properties more homogenous. Histology, DNA and protein 
analysis showed that decellularization was complete and the scaffold was predominantly 
composed of insoluble collagen fibrils devoid of inter-fibrillar matrix or cells.  
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To evaluate cross-linking possibilities, we treated decellularized pericardium with 
UV, PGG and Glut and compared their properties with untreated scaffolds as controls. 
Native, untreated scaffolds degraded quickly in vitro and in vivo, were rapidly invaded 
by host cells, showed signs of remodeling and lack of calcium deposition. UV treatment 
had the most dramatic effects on collagen scaffolds including irreversible and aggressive 
changes in tissue structure, full collapse of the porous configuration and significant 
changes in mechanical properties. UV treated scaffolds appeared to have been partially 
cross-linked because they exhibited initial resistance to collagenase in the first 1-2 days 
of exposure to the enzyme, subsequently losing more than 1/3 of its mass after 7 days in 
collagenase. 
 Upon implantation, UV treated collagen scaffolds were not infiltrated by 
host cells, calcified massively and adhered strongly to their fibrous capsules.  The 
mechanisms of UV-induced collagen cross-linking are thought to include radical 
mediated alterations in aromatic amino acids [18]. These changes may be responsible for 
observed in vitro resistance to collagenase. It is not clear at this point how UV treatment 
induces collagen calcification but we speculate that it does so through dramatic changes 
in molecular structure and ultra structure, including loss of fibrillar architecture [19]. 
Although this cross-linking procedure appears advantageous for tissue engineering 
applications, the propensity of UV treated collagen towards calcification needs to be 
further addressed.  Notably, subdermal implantation in juvenile rats serves as a model for 
calcification [34] as well as for degradation of matrix components and remodeling 
[35,36].  
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Glut treatment effectively stabilized decellularized pericardium against 
collagenase, an expected feature known in the bioprosthetic heart valve field [2]. 
Moreover, Glut-fixed scaffolds exhibited typical mechanical properties and high Td (as 
compared to native collagen). Upon implantation, Glut-fixed collagen calcified to some 
extent, but not to levels reported for bioprosthetic heart valves analysis, where Glut-fixed 
pericardium showed calcification levels of about 100 g/mg [30]. This may be because of 
absence of pericardial cells which are presumably the initial calcification nucleation sites 
[31]. Cell infiltration was noted to occur to some extent in Glut-fixed scaffolds but cell 
numbers did not increase with time and, despite the fact that some infiltrating cells were 
fibroblast-like cells expressing MMPs, Proline-hydroxylase and glycosaminoglycans; it is 
unlikely that these scaffolds will undergo remodeling after implantation.   
PGG treatment revealed substantial initial collagen stabilization versus the action 
of collagenase in vitro, with the potential for reversibility. It should be noted that the in 
vitro collagenase system is an accelerated model for degradation as collagenase activities 
in vivo are not expected to be so harsh [32]. Differential scanning calorimetry analysis 
showed a slightly higher Td when compared to native scaffold and lower than Glut (but 
not statistically different) partially confirming collagenase results. This phenomenon of 
tissue resistance to collagenase in the absence of high Td values was reported previously 
for the Photofix stabilization procedure [33]. Mechanical properties of PGG-treated 
scaffolds were similar to untreated and Glut treated samples except for a relatively higher 
hysteresis (data not shown). Despite effective collagen stabilization, PGG treated 
collagen did not calcify in vivo, suggesting that the nature of the cross-linker may 
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determine the outcome of collagenous implants. Host cells infiltrated implants relatively 
rapidly indicating that PGG-treated collagen is not cytotoxic. Moreover these fibroblast-
like cells secreted MMPs, expressed Proline-hydroxylase and secreted GAGs and thus 
may exhibit true potential for remodeling. Because long-term, adequate control of  local  
inflammation  and  MMP  activities  may  be difficult to achieve and may be 
accompanied by adverse side effects, such as failure of the implant, [20] demonstrating 
that the tissue has potential to remodel, as indicated by the types of cells infiltrating over 
the time course of the in vivo study, further supports the notion that PGG may be a safe 
and effective collagen stabilizing agent. 
Mechanisms of PGG-induced collagen stabilization are not fully understood. PGG 
is a naturally derived polyphenol characterized by a D-glucose molecule derivatized at all 
five hydroxyl moieties by gallic acid, i.e. 3,4,5-trihydroxybenzoic acid (Fig. 2b). 
Polyphenols have a hydrophobic internal core and numerous external hydroxyl groups. 
By virtue of this structure, they react with proteins, specifically binding to hydrophobic 
regions [37], but also establishing numerous hydrogen bonds, showing particularly high 
affinity for Proline-rich proteins [38] such as collagen and elastin [39]. In addition, they 
are efficient antibacterial agents and reduce inflammation and antigenicity [40]. Recently 
we showed that peri-arterial delivery of PGG to rat abdominal aorta prevented aneurysm 
formation or progression and did not elicit any detectable changes in serum liver enzyme 
activities or liver histology, clearly showing that PGG was not toxic at local or systemic 
levels [10]. Moreover, extractables obtained from PGG-fixed tissues exhibited very low 
in vitro cytotoxicity towards fibroblasts and smooth muscle cells [41] and thus can be 
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used safely in tissue engineering applications [42-46]. In current studies we have shown 
that PGG binds strongly to pericardial collagen and this binding was stable for at least 3 
weeks in vivo.   
 
4.5       Conclusions 
Decellularized pulmonary arteries can be prepared by our method to be used as 
the spongiosa layer in our aortic heart valve constructs. Decellularized pericardium 
fulfills many properties required for use in valvular tissue engineering, including 
adequate mechanical properties, minimal cytotoxicity, excellent cell repopulation 
potential and propensity for matrix remodeling. Such collagen scaffolds emerge superior 
to polymer scaffolds in terms of mechanical and biological properties, but also maintain a 
natural tendency to degenerate rapidly in vivo unless stabilized. Glut cross-linking fully 
stabilizes collagen but does not allow for tissue remodeling and also induces calcification 
when implanted subdermally in rats. Conversely, PGG is a mild, non-toxic, reversible 
collagen stabilizing agent capable of controlling tissue degradation. PGG treated collagen 
does not calcify in vivo and supports host cell infiltration and matrix remodeling. In 
contrast, UV treatment induced exstensive changes in the mechanical properties and 
induced profuse calcification of the fibrous collagen scaffold, therefore the use of UV 
cross-linking was no investigated further as a fixation option. In conclusion, PGG 
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INVESTIGATION OF SCAFFOLD ADHERENCE METHODS FOR TRI-
LAYERED TISSUE ENGINEERED HEART VALVES 
(AIM 2) 
 
5.1       Introduction 
Native aortic valve leaflets are complex structures composed of external layers, 
the fibrosa (composed of collagen) on the arterial aspect and the ventricularis (collagen 
and elastin) on the ventricular aspect. The fibrous layers are sustained internally by a 
highly hydrated central spongiosa layer (rich in proteoglycans) that serves as a cushion 
material to mediate deformations of the fibrous layers, allows shearing between the outer 
layers and absorbs compressive forces during valve function [1-3]. Lack of a buffering 
layer results in large shear stress and tissue buckling when subjected to bending [4].  
Tissue engineering, the science of combining scaffolds, cells and specific signals 
to create living tissues is feasible and holds great promise for treatment of heart valve 
disease [5]. Two main strategies have been developed in recent years. The first is based 
on use of decellularized porcine valves followed by in vitro or in vivo repopulation with 
cells of interest. Despite their excellent mechanics, acellular valves are very dense and 
thus difficult to repopulate with desired cells. The second approach employs cell seeded 
polymeric biodegradable matrices [6] or scaffolds built from fibrin [7]. While polymeric 
and fibrin-based scaffolds shown very promising results, decellularized these degradable 
matrices have insufficient strength to withstand arterial pressures immediately after 
implantation.  
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Our novel strategy relies on use of stabilized collagen scaffolds that mimic the 
natural valve fibrous layers, based on decellularized porcine pericardium [8] and delicate, 
highly hydrated porous collagen scaffolds to be used as the middle spongiosa layer. 
Chemically stabilized pericardium has outstanding mechanical properties, a good record 
of implantation in humans as valves, and as reconstructive surgery biomaterial patches in 
other organs [9-15]. To reduce scaffold biodegradation, we have also investigated the use 
of penta-galloyl glucose (PGG), a naturally derived collagen-binding polyphenol [8, 16]. 
No reports to date have documented the use of PGG-stabilized acellular pericardium for 
construction of tissue engineered heart valves. Since the xenoantigen Gal1-3Gal (Gal), 
is responsible for rejection of vascularized organ transplants we are paying special 
attention to Gal detection in decellularized scaffolds [17-21]. 
Recognizing the outstanding mechanical performance of natural valve 
homografts, the vital importance of the three leaflet layers [22], and the need for 
reconstruction of the physiologic valve design, we developed five building blocks for this 
new approach: a) partially stabilized collagenous scaffolds which degrade slowly with 
time, b) anatomically analogous 3-D heart valve shapes made from solid molds, c) tri-
layered constructs that mimic the native heart valve histo-architecture, d) autologous 
multipotent mesenchymal stem cells for repopulation and remodeling and e) mechanical 
cues to induce stem cell differentiation into valvular cells capable of maintaining matrix 
homeostasis.  
To assemble the 3D heart valve structures we developed and implemented use of 
biological adhesives in tissue engineering. At a minimum, these adhesives need to exhibit 
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adequate bond strength and elasticity, long term stability and biocompatibility. In current 
study we chose to implement a modified albumin/glutaraldehyde adhesive for the 
construction of living heart valves. In Chapter 4 we reported on extensive 
characterization of the acellular fibrous pericardial scaffolds and spongy pulmonary 
artery used to mimic the fibrosa and ventricularis layers and spongiosa layers, 
respectively [8]. In current study we describe the use of these novel scaffolds to be used 
as the layers and utilization of a biological glue to assemble the tri-layered constructs.  
 
5.2       Materials and Methods 




PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium 
(www.omnichem.be). Human bone marrow derived stem cells (hBMSCs) were obtained 
from Cell Applications, Inc. San Diego, CA) and all other chemicals were of highest 
purity available from Sigma Aldrich, St. Louis, MO.    
 
 
5.2.2    Methods    
5.2.2.1 Development and testing of the scaffold adhesive 
Since bonding layers of collagen scaffolds is essential for our approach, we 
developed a scaffold adhesive based on protein-aldehyde mixtures, inspired from the 
FDA-approved BioGlue (CryoLife, Kennesaw, GA) developed as a haemostatic agent. 
BioGlue is composed of 45% (w/v) bovine serum albumin and 10% glutaraldehyde 
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solutions which are stored independently in a double-barreled syringe and dispensed 
through a mixing tip to yield a quickly setting gel. Initial testing of the original 
BioGlue on acellular pericardial scaffolds showed that setting time was too short and 
once bonded, of insufficient mechanical strength for creation of engineered heart valves. 
Thus we increased albumin concentration to 55% and decided to apply it in two steps, 
first the protein layer and then glutaraldehyde using single-barreled syringes. This 
approach ensured that the albumin solution first infiltrated several scaffold layers before 
being fully crosslink by the aldehyde. The volumetric ratio of albumin to glutaraldehyde 
was maintained at about 5 to 1. This higher protein concentration reduced the fluidity of 
the solution and allowed for precise positioning of the gluing spots. The new adhesive 
was coined “BTglue” and used in all studies shown below.  
 
5.2.2.2 Lap shear 
The test was performed according to ASTM 2255-05. Fibrous scaffolds were cut 
into 2.5 x 7 cm strips, overlapped over a 1 cm wide area and bonded using the BTglue. 
The specimens were subjected to increasing loads in the testing frame of a MTS Synergy 
100 (Eden Prairie, MN) machine at a crosshead speed of 5 mm/min at room temperature 
(Figure 5.1).  
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Figure 5.1: Testing of the scaffold adhesive. To test bond strength samples were glued 
by partial overlap subjected  to  pullout  forces  and  shear  strength  calculated.  
 
 
The apparent shear strength was calculated as the maximum load divided by the bonded 
area and expressed as Pa.   
 
5.2.2.3 Shear properties 
Squares (20 x 20 mm) of fibrous scaffolds incorporating 10 x 10 mm of spongiosa 
layer were glued together using BTglue as described above. The samples were mounted 
onto a micromechanical testing device (Mach-1 Micromechanical Systems, Biosyntech, 
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Figure  5.2: Testing of the scaffold adhesive. Shear  properties  of  glued  layers  in  
which  spongiosa scaffolds (S) were glued between two fibrous scaffolds (F) using 
BTglue (BG).  
 
 
 A deflection was applied by moving one of the shear plates with the linear positioner of 
the Mach-1 (Figure 5.2 (B)). The shear angle was calculated by finding the arctangent of 
the ratio of deflection over tissue thickness (Figure 5.2 (C)). Shear force was recorded by 
the load cell and converted to shear stress by normalizing to the area of specimen. Shear 
stress-shear angle relationships were compared to fresh valve cusps and 0.5% 
glutaraldehyde-fixed valve cusps.   
 
5.2.2.4 Cytotoxicity studies on BTglue 
Fibrous scaffold samples (15 x 15 mm) were prepared and BTglue (200 l 
albumin followed by 40 l glutaraldehyde) was applied on one surface of the scaffold. 
Scaffolds were then divided into two groups; one group (n = 3) was treated with 50% 
FBS/DMEM mixture for surface passivation (24 hours at 37 
o
C), rinsed and then treated 
for 2 hours in 1% Glycine in PBS for complete aldehyde group neutralization.  
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Figure 5.3: Testing BTglue cytotoxicity. Fibrous collagen scaffolds (CS)  to which a 
single layer of BTglue (BG) was applied were neutralized with FBS/glycine solutions (+) 
or  were  used  without  neutralization  (-)  and  were  then  seeded  with  fibroblasts.   
             
The second group was treated with PBS for 26 hours at 37 
o
C as control. Rat dermal 
fibroblasts (50 x 10
3
 cells per sample) were seeded on the scaffolds, cultured in 
DMEM/10% FBS media and MTS assay and Live/Dead performed 6 days after seeding. 
Number of living cells was calculated from MTS absorbance values (A490) from a 
calibration curve prepared with rat dermal fibroblasts cultured on standard culture plates.  
 
5.2.2.5 Cytotoxicity studies on PGG-treated and glued fibrous scaffolds    
Round fibrous scaffold coupons (3 cm
2
) were prepared and 120 l of BTglue (100 
l albumin followed by 20 l glutaraldehyde) were applied on one surface and on only 
one half of the scaffold, leaving half of scaffold surface untreated with glue. Scaffolds 
were then treated with penta-galloyl-glucose (PGG) (0.1% and 0.15% PGG in 50 mM 
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Figure 5.4:  PGG toxicity testing. Fibrous collagen scaffolds (CS) to which a layer of 
BTglue (BG) was applied on ½  of  the  surface,  were  treated  with  PGG  (0.1%  and  
separately  0.15%),  subjected  to  short  wash  and separately long wash procedures, 
neutralized with FBS/glycine and then seeded with fibroblasts. 
 
Scaffolds not treated with PGG served as controls. Samples were also treated with 0.2% 
glutaraldehyde in PBS as positive cytotoxic controls. Scaffolds were then divided into 
two groups; one group was rinsed in sterile PBS containing 0.02% sodium azide for 20 
minutes at room temperature under gentle agitation (short wash); the second group was 
rinsed in sterile PBS/azide for 5 days with daily changes at room temperature under 
gentle agitation (long wash). Scaffolds were rinsed, treated with FBS and glycine for 
neutralization (as above) and stored in sterile saline. Rat dermal fibroblasts (1x10
5
 cells 
per scaffolds) were seeded on the scaffolds, cultured and MTS and Live/Dead assays 
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performed 5 days after seeding. Results are expressed as percentage viability relative to 
control samples (non-PGG treated group).  
 
5.2.2.6 Tri-layered scaffolds; stability and mechanical properties 
To test whether tri-layered scaffolds maintain stabilization properties, a layer of 
porous spongiosa scaffold was entrapped between two fibrous scaffold layers using 
BTglue as described above. The constructs were then subjected to 0.1% PGG for 24 
hours, long wash protocol, neutralization as above and then exposed to collagenase (6.25 
units/ml, 100 mM Tris buffer, 1 mM CaCl2, 0.02% NaN3, pH=7.8) for up to 20 days at 
37ºC and resistance to enzyme measured by gravimetry.  
 
5.2.2.7 Shear properties 
To assess shear behavior of engineered tri-layered leaflets, 20 x 20 mm squares of 
fibrous scaffolds incorporating 10 x 10 mm of spongiosa layer were glued together using 
BTglue as described above. The two surfaces of glued engineered leaflets were mounted 
onto custom made plates using cyanoacrylate glue and mounted onto a micromechanical 
testing device (Mach-1 Micromechanical Systems, Biosyntech, MN) and sheared to 
mimic physiologic movements of valve leaflets. A deflection was applied by moving one 
of the shear plates with the linear positioner of the Mach-1. The shear angle was 
calculated by finding the arctangent of the ratio of deflection over tissue thickness. Shear 
force was recorded by the load cell and converted to shear stress by normalizing to the 
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area of specimen. Shear stress-shear angle relationships of tissues were then obtained and 
properties were compared to fresh valve cusps and glutaraldehyde-fixed valve cusps.   
 
5.2.2.8 In vivo evaluation of glued scaffolds 
Tri-layered constructs were prepared by gluing one 10 x 10 mm spongiosa 
scaffold between two fibrous layers cut between 10-15 x 10-15 mm using a 1-2 mm wide 
line of glue around the four sides. Samples were treated with 0.1% PGG, long wash 
procedure and neutralization and implanted subdermally (two implants per rat) in male 
juvenile Sprague-Dawley rats (n = 10) as described before [8]. High density polyethylene 
(HDPE) samples were also implanted as negative controls as per ISO-10993 standards (n 
= 3 rats) and sutured fibrous scaffolds served as controls.          
               
              
Figure  5.5: Scaffolds for implantation. (A) is a representative scaffold implanted 
showing the spongy scaffold between two layers of fibrous scaffold (spongy scaffold 
visualized due to the translucency of the fibrous scaffold. (B) shows the sutured scaffold 
that was implanted as a control. 
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The animal protocol was approved by the Animal Research Committee at 
Clemson University and NIH guidelines for the care and use of laboratory animals (NIH 
publication #86-23 Rev. 1996) were observed throughout the experiment. The rats were 
humanely euthanized at 5 weeks after surgery and samples retrieved for histology, 
calcium assay and matrix metalloproteinase (MMP) analysis [8]. To test for remote organ 
toxicity, liver, heart and kidney samples were collected from each animal.  
For histology, paraffin sections were stained with Hematoxylin and Eosin, 
Masson’s Trichrome and Alizarin Red stains. For identification of infiltrating cell types, 
immunohistochemistry was performed as described before [8] using mouse anti-rat 
monoclonal antibodies to macrophages (1:200 dilution, Chemicon, Temecula, CA), 
vimentin (1:500 dilution, Sigma, St. Louis, MO), type III collagen (1:200 dilution, 
Sigma, St. Louis, MO) and fibronectin (1:100 BD Labs) and sections were lightly 
counter-stained with Hematoxylin. As positive controls we used same antibodies to stain 
normal rat spleen (macrophage control) and rat skin (fibroblast control) in parallel with 
the explant sections.  
 
Statistics   
Results are represented as means ± the standard error of the mean (SEM). Statistical 
analysis was performed with one way Analysis of Variances (ANOVA) and results were 





5.3       Results 
5.3.1    Scaffold adhesive 
 
Our novel scaffold adhesive (BTglue) showed good bonding strength when 
compared to other available medical grade glues (Figure 5.6) .  BT-glue was five-fold 
stronger than fibrin glue and 20-plus stronger than silicon glue. When compared to 
Dermabond, a cyanoacrylate-based glue, BTglue was weaker; however, cyanoacrylates 
are not FDA-approved for internal use (Figure 5.6). Mechanical analysis revealed that 
the glued tri-layered leaflets were found to be stiffer than native porcine aortic leaflets but 
not different from glutaraldehyde-fixed porcine leaflets, and allowed shearing to lower 
angles (Figure 5.7).  
 
Figure 5.6: Testing of the scaffold adhesive. To test bond strength samples were glued by 
partial overlap  subjected  to  pullout  forces  and  shear  strength  calculated.  Values  are 





Figure 5.7. Testing of the scaffold adhesive. Test results showing shear stress-shear 
angle curves of the tri-layered construct; groups A and B are replicate experiments. 
Native porcine aortic valve leaflets and glutaraldehyde-fixed (Glut) leaflets were also 
plotted as a comparison (data provided by Jun Liao, University of Mississippi). 
 
Additionally, trichrome evaluation of the samples prepared for lap shear showed glue 
infiltration into and between the collagen fibers of the fibrous scaffolds. 
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Figure 5.8:  Testing of the scaffold adhesive. To test bond strength samples were glued 
by partial overlap  subjected  to  pullout  forces. Trichrome evaluation of these samples 




BTglue was quite cytotoxic when left untreated, but was rendered very cell friendly and 
supported fibroblast proliferation after treatment with FBS and glycine to neutralize 




Figure 5.9: Cytotoxicity studies (A) Phase contrast image showing living cells. (B) Dead 




Figure 5.10: Cytotoxicity studies (A) Live cells covering both the glue and the scaffold 
surfaces. (B) Live cells covering the glue surface. Bars are 100 µm.  
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Figure 5.11: Testing BTglue cytotoxicity. Fibrous collagen scaffolds (CS) to which a 
single layer of BTglue (BG) was applied were neutralized with FBS/glycine solutions (+) 
or were  used  without  neutralization  (-)  and  were  then  seeded  with  fibroblasts.  
Cells  numbers  were measured at time zero and after 6 days using the MTS assay. 
*denotes statistical significance.  
 
 
The glued pericardial constructs showed moderate resistance to collagenase (13%, 19% 
and 23%  mass  loss  after  7,  14  and  20  days,  respectively) possibly due to 
glutaraldehyde cross-linking of scaffold collagen in the gluing areas. 
 
                
 




5.3.2    PGG cytotoxicity 
To test toxicity of PGG-treated and glued samples, glued scaffolds were treated 
with increasing concentrations of PGG, rinsed shortly or for several days (long wash) and 
seeded with fibroblasts . MTS and Live/Dead results showed that long wash significantly 
improved cell viability as compared to the short wash protocol (p < 0.05) (Figure 9,10, 
12).  
 
                
Figure 5.12: PGG toxicity testing. Fibrous collagen scaffolds (CS) to which a layer of 
BTglue (BG) was applied on ½  of  the  surface,  were  treated  with  PGG  (0.1%  and  
separately  0.15%),  subjected  to  short  wash  and separately long wash procedures, 
neutralized with FBS/glycine and then seeded with fibroblasts. Cell numbers  were  




Enzyme tests showed that neither treatments changed resistance to collagenase (data not 




5.3.3    In vivo studies 
To evaluate biocompatibility of our tri-layered constructs we implanted samples 
subdermally in juvenile rats and analyzed them after 5 weeks. Animals exhibited similar 
weight gain (p < 0.05) indicating lack of systemic toxicity for all implants. In addition, 
histological analysis of liver, heart and kidney samples indicated lack of remote organ 
toxicity for all implants (data not shown). Implants were surrounded by a thin capsule 
and showed good integration into host subdermal tissues. As expected, negative control 
HDPE implants induced minimal host reactions which were limited to a very thin 
capsule. 
Histological analysis of implanted tri-layered scaffolds revealed that scaffolds 
maintained their integrity and the glued areas did not separate or delaminate. The 
spongiosa scaffolds were found intact and no host cells were present inside the glued 
scaffold “pockets”, indicating that the seal provided by the BTglue was not compromised. 
Host cells were present around the implants but not within the thickness of the acellular 
pericardium. Cells mostly associated with external collagen fibers which exhibited a 
“frayed” or unraveled aspect indicative of possible collagen degeneration (Figure 5.13). 
In many areas degraded collagen fibers were replaced by new matrix, as detected by 




Figure  5.13.  Implantation  results.  PGG-treated  fibrous  collagen  scaffolds  (CS)  
containing  spongiosa scaffolds (SP) glued with BTglue (BG) were implanted 
subdermally and analyzed by histology after 5 weeks. (A-C) H&E stain of (A) 





Figure 5.14.  Implantation  results. PGG-treated  fibrous  collagen  scaffolds  (CS)  
containing  spongiosa scaffolds (SP) glued with BTglue (BG) were implanted 
subdermally and analyzed by histology after 5 weeks. Trichrome stain (collagen blue, 
cells dark pink) of (D) unimplanted, and (E, F) implanted scaffolds. 
 
 
Matrix metalloproteinase (MMP) activity was measured in explants from both 
groups using gelatin zymography (not shown); one major protease was identified in tissue 
extracts, namely MMP-2, migrating at around 65-80 kDa. These observations suggest 
that PGG-treated collagen scaffolds are not cytotoxic, are slowly degradable in vivo and 
may possibly support matrix remodeling. Immunohistochemistry revealed that the 




        
Figure  5.15: Implantation results: Immunohistochemical staining for (A,B and insert) 
macrophages, (C,D and insert) vimentin, (E,F and insert) collagen type III,  fibronectin, 
(G,H and insert) showing positive results. (A,B,D,F H = 20X magnification)(C,E,G = 10x 
magnification)        
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Chemical analysis revealed a very low tendency towards calcification of our tri-
layered glued constructs (5 ± 2 g Ca/mg dry). Alizarin Red S staining confirmed these 
data and revealed calcium deposits in only 1 sample out of 6 analyzed (Figure 5.16). 
Calcium deposits appeared to associate with the glue and with the PGG-treated collagen 
scaffold in the vicinity of the BTglue suggesting that traces of glutaraldehyde may induce 
calcium deposition. Overall these observations support earlier data which showed that 
despite effective stabilization, PGG treatment does not induce collagen calcification [8].  
 
 
Figure 5.16: Implantation results. PGG-treated fibrous  collagen  scaffolds  (CS)  
containing  spongiosa scaffolds (SP) glued with BTglue (BG) were implanted 
subdermally and analyzed by histology after 5 weeks. Alizarin red stain  for  calcium  
deposits  in  the  only  sample  (out  of  6)  which  showed  signs  of  calcification. 
 
 
5.4       Discussion 
For heart valve assembly, gluing techniques were developed and tested in vitro 
and in vivo. To our knowledge this is a first report on scaffold gluing techniques for heart 
valves tissue engineering. The albumin/glutaraldehyde glue has evolved conceptually 
from the very popular gelatin-resorcinol-formaldehyde (GRF), still in use throughout 
Europe and the USA [23]. Histology showed that application of the BTglue in two steps 
allowed albumin to first infiltrate several layers of collagen fibers within the scaffold 
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surfaces before application of the glutaraldehyde component. The bond strength of 
BTglue was found to be adequate for our applications and during shearing tests, 
bioreactor studies and subdermal implantation, the glue maintained its integrity, stability 
and an ability to seal. These tests, while elucidating the importance of a spongiosa layer 
and validating the effectiveness of the Bioglue, showed that adhering two pieces of 
pericardium together allowed for some shearing, revealing that the shear properties 
within our tissue engineered construct will rely heavily on the pulmonary artery scaffold, 
necessitating a tri-layered assembly. This is further substantiated by the fact that our test 
samples were adhered together at all edges completely by BTglue, with little spongiosa 
represented by the pulmonary artery scaffold. The BTglue in the shear stress-shear strain 
experiment represents the case by which all shearing is dependent on the amount of 
BTglue used, not the spongiosa. This scenario is a worst-case scenario, by which the glue 
makes the entire construct more stiff and influences the shear properties. This further 
highlights the need to perfect the glue-adherence points and amounts whereby the amount 
of glue and position of gluing will not have a deleterious effect on stiffness and ability of 
the layers to shear. 
Scaffolds adhered with BTglue exhibited resistance to proteases and were easily 
rendered cytocompatible by neutralization. There is a possibility that the presence of glue 
between the spongiosa and fibrosa/ventricularis layers will inhibit homogeneous 
mesenchymal stem cell distribution in all three layers. To address this issue, we must 
optimize the assembly process to determine precise positioning of the gluing “points” and 
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the minimal amount of glue required to maintain integrity while allowing for cell 
migration within all three layers.  
 Upon sub-dermal implantation of the glued construct we observed one single area 
of calcification in close apposition with the glue, indicating that enhanced neutralization 
of aldehyde groups would be needed in the future. We have shown earlier that simple 
amines and diamines are capable of neutralizing effects of glutaraldehyde [24]. Perfecting 
the gluing application will also possibly alleviate this potential effect. The Glut-mediated 
calcification is further supported by the lack of cellular infiltration into the spongiosa 
layer. Lack of cellular infiltration can prove advantageous in future studies in which cell-
seeded pulmonary artery scaffolds are inserted into the construct. The scaffold can thus 
serve as a immune privileged site, by which any type of cell can be seeded onto the 
scaffold.  
In current study we used PGG as a stabilizer for the fibrous collagen scaffolds. 
The most effective method to create heart valve-shaped constructs from decellularized 
pericardium was treating dry scaffolds with PGG. In vitro studies showed that PGG, 
when used in concentrations higher than 0.15% could be cytotoxic [25]. To achieve an 
optimum balance of cell viability and scaffold stability, we chose to use 0.1% PGG 
followed by rinsing and neutralization. PGG treatment of the BTglue was not detrimental 
to gluing properties, confirming earlier studies which showed that use of glutaraldehyde 
in conjunction with PGG had a synergistic effect on tissue stabilization [26]. In vivo 
studies also showed that although most of the fibrous collagen scaffold was intact after 5 
weeks implantation, there was some unraveling of the collagen fibers on the outside 
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edges of the implants associated with infiltration of macrophages, fibroblasts and signs of 
remodeling.   
 
5.5       Conclusions 
This study is a stepping stone towards development of a novel approach to heart 
valve tissue engineering. Recognizing the importance of each of the three layers in a 
native aortic heart valve, we have taken one step towards this goal by utilizing a 
bioadhesive that may hold the layers together. The BTglue was found to possess the 
mechanical properties necessary to maintain adhesion of the layers together while at the 
same time allowing cellular survival and growth on our glued scaffolds. This technique of 
adhering different scaffolds together to form a single tri-layered construct thus holds 
promise for applications in heart valve tissue engineering. 
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MOLDING, ASSEMBLY, AND BIOREACTOR TESTING OF TRI-LAYERED 




6.1       Introduction 
  Our novel strategy relies on use of stabilized collagen scaffolds that mimic the 
natural valve fibrous layers, based on decellularized porcine pericardium [8] and delicate, 
highly hydrated porous collagen scaffolds to be used as the middle spongiosa layer. 
Chemically stabilized pericardium has outstanding mechanical properties, a good record 
of implantation in humans as valves, and as reconstructive surgery biomaterial patches in 
other organs [9-15]. To reduce scaffold biodegradation, we have also investigated the use 
of penta-galloyl glucose (PGG), a naturally derived collagen-binding polyphenol [8, 16]. 
No reports to date have documented the use of PGG-stabilized acellular pericardium for 
construction of tissue engineered heart valves. Since the xenoantigen Gal1-3Gal (Gal), 
is responsible for rejection of vascularized organ transplants we are paying special 
attention to Gal detection in decellularized scaffolds [17-21]. 
Recognizing the outstanding mechanical performance of natural valve 
homografts, the vital importance of the three leaflet layers [22], and the need for 
reconstruction of the physiologic valve design, we developed five building blocks for this 
new approach: a) partially stabilized collagenous scaffolds which degrade slowly with 
time, b) anatomically analogous 3-D heart valve shapes made from solid molds, c) tri-
layered constructs that mimic the native heart valve histo-architecture, d) autologous 
multipotent mesenchymal stem cells for repopulation and remodeling and e) mechanical 
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cues to induce stem cell differentiation into valvular cells capable of maintaining matrix 
homeostasis.  
In current study we describe development of molds to be used as the forms on 
which to layer the 2 scaffolds we have developed and the utilization of our biological 
BTglue to assemble the tri-layered constructs. 
 
6.2       Materials/Methods 
6.2.1 Materials 
 High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl-glucose, 
PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium 
(www.omnichem.be). Silicone was obtained from Copy Flex Liquid Silicone, Cincinnati, 
OH (www.makeyourownmolds.com). 
 
6.2.2    Methods 
6.2.2.1 Construction of molds for anatomically correct valves 
Whole porcine hearts collected at a local abattoir were brought to the lab on ice, 
rinsed with saline, and aortic and pulmonary valves dissected together with preservation 
of the entire anatomy of the cardiac base. Valves were then fixed for 48 hours in 0.6% 
glutaraldehyde (Glut) in 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
buffered saline (pH=7.4) at 22ºC. At the onset of fixation the aortic heart valve cusps 
were lightly stuffed with Glut-imbibed cotton balls to maintain the valve in closed 
position. After removal of the cotton balls and rinsing, liquid Silicone (Copy Flex Liquid 
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Silicone, Cincinnati, OH) was poured into the aortic valve via the ascending aorta, while 
the coronaries were plugged to prevent leakage with pegs made from the silicone, and the 
silicone allowed to harden for 24 hours at room temperature. Final molds could easily be 
removed from the aorta.  
After removal of the mold, a negative mold was formed in which the collagen 
scaffold could be pressed between to form the shape of the aortic valve. Briefly, the 
initial mold was coated with a silicone grease, to allow for easy removal) and placed into 
a specimen cup filled with approximately 80 mls of silicone. The silicone was allowed to 
harden for 24 hours at room temperature. Finally, the mold was easily extracted from the 
specimen cup leaving an exact negative mold of the molded aortic valve in the specimen 
cup. The specimen cup was then cut away from the negative mold.  
 
6.2.2.2 Construction of single layer, anatomically correct valves 
Fibrous collagen scaffolds prepared from porcine pericardium (see Chapter 4) 
were placed onto the molds, with the fibrous side of the pericardium in direct contact to 
the mold, and then the mold s pressed into the negative mold to ensure complete shaping 
of the collagen scaffold. After removal of the mold from the counter mold, the collagen 
scaffold was adhered to the counter mold with pins in the central gap, along the edges of 
the cusp, and along the base of the valve and air dried for 48 hours in a sterile bio-hood. 
The dried scaffold was then removed and fixed with 0.3% PGG for 24 hours. After 
fixation, the individual leaflets were separated by incisions to result in the 3 distinct 
leaflets. To test functionality of the heart valve-shaped fibrous scaffolds they were 
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mounted onto a silicone mock aorta support in a home-made pulse duplicator heart valve 
bioreactor tester system (described in detail in manuscript by Leslie Sierad et. al. 
accepted to Cardiovascular Engineering and Technology, May 2010). and cycled at about 
1 Hz. Still frames were captured from digital movies using video editing software 
(VideoStudio 9, ULead Systems Inc., Torrance, CA). 
 
6.2.2.3 Construction of tri-layered, tissue engineered valves 
To test the association of the 3 layers and create layered constructs that resemble 
the valve histo-architecture, two  sheets  of  fibrous pericardial  scaffolds  were  
superimposed  and  a  small  sheet  of spongy scaffold was entrapped between the two 
fibrous scaffolds. The edges were then sealed by staples.  
  To create the histologically and anatomically correct scaffold constructs, molds 
formed above were used for the following purposes. Two fibrous collagen scaffolds 
prepared from porcine pericardium (described above) were placed onto negative molds 
(with fibrous sides placed together) and air dried for 48 hours in a sterile bio-hood. The 
scaffold was then separated and dissected at the level of the cusps. The two identical 
valve-shaped scaffolds were overlapped (with fibrous sides placed together again) and 
assembled by applying BTglue to the entire scaffold surface corresponding to the aorta 
and the sinuses, leaving the cusps un-attached.  For bioreactor testing, the original 
porcine aortic root (from which the mold was cast) was rinsed in saline, the three native 
valve cusps excised by dissection and the assembled engineered valve was secured inside 
the aortic root using sutures and BTglue. To test functionality of the constructs they were 
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mounted onto our heart valve bioreactor. The device consists of a valve mounting ring 
assembly encased between a ventricular chamber and an aortic chamber filled with cell 
culture medium. The medium is pushed through the valve by a flexible silicone 
membrane diaphragm connected to an air pump. Extensive testing has shown that the 
bioreactor ensures comparable pumping functions to a living heart (data not shown-see A 
Pulsatile Bioreactor for  Conditioning Tissue Engineered Heart Valves, MS Thesis by 
Leslie Sierad, Clemson University, May 2009). The tissue engineered valve was 
subjected to open-close cycles at 60 beats per minute, 40/20 mmHg, 10 mL stroke 
volume, at 37 
0
C, 5% CO2 for 8 days. Cusp movements and still frames were captured 
with a Logitech webcam.  
 
6.3       Results 
6.3.1    Construction of molds for anatomically correct valves 
The long term aim of our studies is to create anatomically correct scaffolds to be 
used as off-the-shelf constructs for heart valve tissue engineering. To create structures 
that mimic the heart valve anatomy, we used silicon molds from porcine heart valves.  
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Figure 6.1: Construction of molds for anatomically correct valves. Silicone molds were 
prepared from porcine heart valves. 
                             
 
Figure 6.2: Construction of molds for anatomically correct valves. Silicone molds were 
prepared from porcine heart valves seen in Figure 6.1. RC – right coronary; LC – left 
coronary; a, b, c – the three leaflets. 
 
 





Figure 6.3: Construction of molds for anatomically correct valves. Silicone molds were 
prepared from porcine heart valves seen in Figure 6.1 and negative molds were formed 
from the direct aortic valve molding. 
 
 
6.3.2    Construction of single layer, anatomically correct valves 
Scaffolds dried onto such molds adopted the valve structure down to very fine details 
(Figure 6.4).  This shape was maintained after rehydration and PGG stabilization. The 
scaffold obtained a yellowish tint upon PGG fixation (Figure 6.5). The single-layer valve 
was then mounted in our custom made bioreactor (Figure 6.6, 6.7) and  functioned 




        
Figure 6.4: Construction of Single Layer, anatomically correct valves. Wet fibrous 
scaffolds (A) were dried onto molds. Upon removal, they retained the shape of the aortic 










Figure 6.5: Construction of Single Layer, anatomically correct valves. Rehydrated/PGG 
fixed scaffold with the 3 leaflets dissected (C). (A) shows the ventricular side, while (B) 






Figure 6.6: Picture and computer aided drafting representation of assembled bioreactor. 




Figure 6.7: Cross-sectional view of the bioreactor demonstrating the pumping actions 
during systole and diastole. Black arrow signifies where the tissue engineered valve is 
mounted (Courtesy of Lee Sierad).  
 
 
Figure 6.8: Still frames acquired from digital movies of a valve-shaped fibrous scaffold 
tested for functionality. The three leaflets are labeled A, B, and C.  
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6.3.3    Construction of tri-layered, tissue engineered valves 
 The long term aim of our studies is to build not only anatomically correct 
scaffolds but these scaffolds must be histologically correct structures for heart valves. To 
this end we have used different collagen scaffolds to form the 3 layers of the native aortic 
valve.  
Histological analysis showed a unique tri-layered of the tri-layered structure  
resembling  the  heart  valve  histo-architecture  (Figure 6.9)  where  a  spongiosa  layer  
(S)  is  entrapped  between  two fibrous layers (F).  
 
Figure 6.9:  Tri-layered scaffolds made by entrapping a sheet  of  spongy  (S)  scaffold  
between two  fibrous  (F)  scaffolds   and   edges  sealed  by staples   (A).   Histology   
and   H&E stain   (2.5   x) showed a  fair  resemblance  to  natural  heart  valve structure 
(B).      
 
 
Thickness of fibrous scaffold is  0.125  +/-  0.005 mm (mean   +/-   SEM   for n=40),   
and   thus   the   total thickness  of  tri-layered scaffolds  is expected  to  be less than 0.5 
mm (3 x 0.124).  
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For making anatomically correct tri-layered constructs, after drying the two 
fibrous scaffolds on their molds, the scaffolds have acquired the shape of the aortic valve 
including the very delicate details of the 3D corrugations, which could then be preserved 
permanently by stabilization with PGG (see Figure 6.4 and 6.5). Two identical valve-
shaped scaffolds were then overlapped and assembled using BTglue (Figure 6.10).  
The entire construct was then sutured into the aortic root from which the silicone mold 
shape was originally acquired. The reconstructed valve fit flawlessly within the natural 
root (Figure 6.10 and 6.11).  
Functionality testing of the heart valve-shaped scaffolds showed good leaflet 
coaptation upon closure and adequate opening characteristics (Figure 6.11).    
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 Figure 6.10: Valve-shape constructs were assembled by overlapping two identical 
fibrous scaffolds (A and B) and inserting a piece of spongy scaffold between the two 
layers (E, arrow shows spongy scaffold). BTglue was used at the open edges of the cusps 
(arrow in C)  and both BTglue and sutures were placed at the level of valve wall, sinuses 
and cusp insertion points (D). 
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Figure 6.11: Tri-layered tissue engineered heart valve sutured inside a porcine aortic   
root.   (A,C) are top view and (B,D) are bottom view.  
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Figure 6.12: Bioreactor testing of  the tissue engineered heart valve (A,C) showing 
comparable  function  to  a  living  porcine  aortic heart valve (B,D).  
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6.4       Discussion 
The long term aim of our studies is to create anatomically correct scaffolds to be 
used as off-the-shelf constructs for heart valve tissue engineering. For this purpose we 
created silicone molds from porcine aortic heart valves and then modeled decellularized 
porcine pericardium into anatomically correct scaffolds. After drying them in their molds, 
the scaffolds have acquired the shape of the aortic valve including the very delicate 
details of the 3D corrugations, which could then be preserved by exposure to PGG. Two 
identical valve-shaped scaffolds were then overlapped and assembled using BTglue and 
sutured into the aortic root from which the silicone mold shape was originally acquired, 
to mimic a potential clinical scenario. Functionality testing of the heart valve-shaped 
scaffolds showed good leaflet coaptation upon closure and good opening characteristics . 
However, there is a possibility that the presence of glue between the spongiosa and 
fibrosa/ventricularis layers will inhibit homogeneous mesenchymal stem cell distribution 
in all three layers. To address this issue, we are currently optimizing the assembly process 
to determine precise positioning of the gluing “points” and the minimal amount of glue 
required to maintain integrity while allowing for cell migration within all three layers. 
In an envisioned clinical scenario (see Project Rationale for complete details), 
imaging data obtained from the patient’s valve would be translated into solid molds using 
a stereolithography system and the solid molds used for valve construction. Our current 
approach of using solid molds formed by pouring liquid silicone into an intact valve will 
obviously not be useful in a clinical setting, but our proof of concept work with the solid 
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molds demonstrates that our scaffolds can be fashioned into anatomically and 
histologically valve constructs comparable to the native aortic valve.  
 
6.5       Conclusions 
This study is a stepping stone towards development of a novel approach to heart 
valve tissue engineering. We utilized two types of acellular collagen scaffolds, a flat 
collagen sheet of high tensile strength and malleability and a highly hydrated scaffold 
that mimics valvular spongiosa layer. The scaffolds were assembled into anatomically 
analogous 3-D heart valve shapes using novel protein-based glue and tested in our  
custom-made bioreactor for functionality. While many aspects and details need to be 
optimized as far as scaffold assembly and animal testing are concerned, this approach 
appears promising for our envisioned translational scenario.        
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STEM CELL DIFFERENTIATION WITHIN TRI-LAYERED TISSUE 
ENGINEERED HEART VALVES 
(AIM 4) 
 
7.1       Introduction 
The predominant cell populations in heart valves, valvular interstitial cells (VICs), 
continuously secrete matrix components such as collagen, GAGs and as well as matrix 
degrading enzymes such as matrix metalloproteinases (MMPs) and other matrix 
degrading enzymes such as GAG-degrading enzymes that mediate remodeling that 
mediate remodeling [1-3]. VICs exhibit a dynamic phenotypic spectrum ranging from 
quiescent fibroblast-like cells (characterized by expression of vimentin, fibroblast surface 
antigen and low expression of alpha-smooth muscle cell actin and MMP-13), to activated 
VICs, assimilated as myofibroblasts (characterized by proliferation, migration and high 
expression of alpha-smooth muscle cell actin) [4-8].  Overall,  permanent  interactions  
between mechanical  forces,  valvular  cells  and  the  matrix  dictate  adaptability  and  
durability  of  heart  valves. Duplication of these structures and interactions in a man-
made device is truly the bioengineers’ dream and has the potential to provide tremendous 
clinical benefits.   
Cell sourcing for seeding heart valve scaffolds includes differentiated cells 
(smooth muscle cells, fibroblasts) and mesenchymal or embryonic stem cells [9, 10]. 
Other cell sources include peripheral blood and human umbilical cord blood [11]. Upon 
biochemical and/or mechanical stimulation, most of these cells express markers of 
quiescent VICs such as vimentin, among others [12].   
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 As stated before, our approach aims to combine partially stabilized collagen 
scaffolds that can be formed into anatomically analogous  tri-layered, 3-D heart valve 
shapes made from solid molds that mimic the native heart valve histo-architecture. Also, 
we aim to use autologous multipotent mesenchymal stem cells for repopulation and 
remodeling and mechanical cues to induce stem cell differentiation into valvular-like 
cells capable of maintaining matrix homeostasis. To assemble the 3D heart valve 
structures we developed and implemented use of biological adhesives in tissue 
engineering, as discussed in Chapter 5. We have reported on extensive characterization of 
the acellular fibrous pericardial scaffolds used to mimic the fibrosa and ventricularis 
layers [13]. In current study we describe the use of our novel scaffolds to be used as the 
spongiosa layer that can be seeded with adult stem cells. We also show that bioreactor 
conditioning of stem cell-seeded tri-layered valves induced differentiation into VIC-like 
cells.       
 
7.2       Materials and Methods 
7.2.1    Materials 
 High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl-glucose, 
PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium 
(www.omnichem.be). Human bone marrow derived stem cells (hBMSCs) were obtained 
from Cell Applications, Inc. San Diego, CA) and all other chemicals were of highest 
purity available from Sigma Aldrich, St. Louis, MO.    
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7.2.2    Methods 
7.2.2.1 Cell seeding of spongy scaffolds 





marrow derived stem cells (hBMSCs) by direct drop wise pipetting of cell suspensions 
onto scaffolds and culturing for 2 days before being inserted into the fibrous scaffold 
construct (described fully in Chapter 6). Briefly, two identical valve-shaped scaffolds 
were overlapped and assembled by applying BTglue to the entire scaffold surface 
corresponding to the aorta and the sinuses, leaving the cusps un-attached.  For bioreactor 
testing, the original porcine aortic root (from which the mold was cast) was rinsed in 
saline, the three native valve cusps excised by dissection and the assembled engineered 
valve was secured inside the aortic root using sutures and BTglue. The entire construct 
was then rinsed and neutralized with 50% FBS and glycine (as described in Chapter 6). 
To finalize assembly, stem cell-seeded spongiosa (see below) was inserted between the 
two cusp-shaped scaffolds and the free cusp edges sealed with a thin line of BTglue. The 
edges of the cusps were rapidly neutralized by dipping in glycine.  
 
7.2.2.2 Cell seeded tri-layered construct bioreactor conditioning 
To test functionality of the constructs they were mounted onto our heart valve 
bioreactor (described in detail in manuscript accepted to Cardiovascular Engineering and 
Technology, May 2010). The device consists of a valve mounting ring assembly encased 
between a ventricular chamber and an aortic chamber filled with cell culture medium. 
The medium is pushed through the valve by a flexible silicone membrane diaphragm 
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connected to an air pump. Extensive testing has shown that the bioreactor ensures 
comparable pumping functions to a living heart (data not shown-see A Pulsatile 
Bioreactor for  Conditioning Tissue Engineered Heart Valves, Thesis by Leslie Sierad, 
May 2009). The stem cell-seeded tissue engineered valve was subjected to open-close 
cycles at 60 beats per minute, 40/20 mmHg, 10 mL stroke volume, at 37 
0
C, 5% CO2 for 
8 days. Cell viability after 8 days of bioreactor conditioning was performed by Live/Dead 
stain. Cells were also stained with mouse anti-human vimentin and separately with anti 
alpha-smooth muscle cell actin (1:200 dilutions) and AlexaFluor-594 (Molecular Probes, 
Eugene, OR) tagged secondary antibody for immunofluorescence detection. Porcine 
valvular interstitial cells (VICs) were also stained for comparison.      
 
7.3       Results 
7.3.1    Cell seeding of Spongy Scaffolds 
 The overall goal of this project is to assemble a tri-layered construct to mimic the 
ultrastructure of the native heart valve. The viability and adaptability of the tri-layered 
construct is contingent on the viability of the cells incorporated into the construct (see 
Figure 7.1). Therefore, we tested several methods of introducing stem cells into the 
spongiosa layer. The first of which, injection of hBMSCs into the spongiosa layer after 
the spongy scaffold has been inserted between the fibrous scaffolds, yielded few viable  
cells upon removal of the spongiosa layer after 24 hour dynamic functionality testing of 
the entire construct and evaluation by Live/Dead (data not shown).   
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Figure 7.1: Schematic of the tri-layered construct with location of introduced stem cells.  
 
 The second method of cell seeding involved the pre-incubation of the spongy 
scaffolds with hBMSCs and inserting of the pre-seeded spongy scaffold between the two 
fibrous scaffolds. This yielded more viable cells (see section 7.3.2 below for cell viability 
results) and is thus the method that was chosen.  
To summarize the procedure of valve assembly and spongiosa insertion, fibrous 
scaffolds were dried onto molds and PGG treated. The valve-shape constructs were then 
assembled by overlapping two identical fibrous scaffolds using BTglue and sutures 
placed at the level of valve wall, sinuses and cusp insertion points. Stem cell-seeded 
spongiosa scaffolds (arrow in Figure 7.2c) were inserted between the fibrous scaffolds 
inside the cusp structure and edges sealed with BTglue. Finally, the entire construct was 
sutured inside the original aortic root from which the mold was cast. 
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Figure 7.2: Valve-shape constructs (a, b, c in (A) denotes individual leaflets) were 
assembled by overlapping two identical fibrous scaffolds (B) using BTglue and sutures 
placed at the level of valve wall, sinuses and cusp insertion points (C). Stem cell-seeded 
spongiosa scaffolds (E-arrow) were inserted between the fibrous scaffolds inside the cusp 
structure and edges sealed with BTglue. (F) The construct was sutured inside the original 












Functionality testing of the tri-layered construct yielded fair results. After 2 days of 
conditioning in sterile culture media, one cusp (a) had to be excised due to a superfluous 
amount of tissue that impeded the opening and closing of the construct (Figure 7.3,C), 
after which the bi-leaflet construct opened and closed more normally. This highlights 
the need for more investigation into the assembly process (see Recommendations for 
Future Work). 
 
          
Figure 7.3: Initial functionality testing of the valves in a pulsatile bioreactor; aortic view 
(A and B), with  a, b, c – the three leaflets. Stem cell-seeded tissue engineered valve 
being subjected to bioreactor conditioning in sterile cell culture media (red) (C and D). 
External diameter of the porcine valve used in this study was about 23 mm.  
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7.3.2    Cell seeded tri-layered construct bioreactor conditioning 
 
A short-term bioreactor study, in which the pulmonary artery scaffolds were 
seeded with hBMSCs, revealed that the seeding procedure for the spongiosa and 
subsequent insertion into a “sandwich” construct did not affect cell survival after 3 days 
while supported signs of stem cell differentiation (data not shown) . After 8 days in the 
heart valve bioreactor, cell viability was maintained at more than 90% and hBMSCs 
elongated significantly and stained positive for vimentin, but very weak for alpha-smooth 
muscle cell actin. Although absolute clear markers for VICs are still a matter of debate, 
this staining pattern is indicative of non-activated, quiescent VICs [8] (Figure . Static 
controls were also alive, but cells did not elongate and stained very weakly for vimentin 
and actin (Figure 7 9).  
 
Figure 7.4 Control VICs stained for actin (A-C) and vimentin (D) (both red, with 
overlapped DAPI blue nuclear stain). Bar are 100 m. 
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Stem cells retrieved from the bioreactor shared similarities to native VICs, indicating that 
physiologic mechanical stimuli offered by our 3D tissue engineered heart valve 
constructs and the bioreactor encouraged differentiation of stem cells into VIC-like cells, 
a much sought-after outcome of valvular tissue engineering. Moreover, these results were  
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Figure 7.5 Bioreactor results with stem cell-seeded valves after 8 days. Cell viability was 
confirmed using Live/Dead stain (live cells green, dead cells red) in(A). (B) shows DAPI 
nuclear staining confirming presence of cells. (C-D) show immunofluorescence staining 
(red, with overlapped DAPI blue nuclear stain) showing elongated, vimentin positive 




obtained within constructs made from collagen scaffolds that would resist physiologic 
pressure immediately after implantation.      
 
Figure 7.6 Cell viability (A) and DAPI staining (B) in static controls. 
Immunofluorescence staining showing very few vimentin-positive cells (C and D). Bars 
are 100 m. 
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7.4       Discussion   
 Our vision of a potential translational scenario using stabilized collagen scaffolds 
and autologous stem cells involves the following steps. After initial diagnosis and  
collection  of  mesenchymal stem cells from the  patient, imaging of the diseased heart 
valve would  provide anatomical coordinates for reconstruction of the heart valve 
geometry into solid molds using appropriate software and hardware. Concomitant with 
stem cell isolation, valves will be made from decellularized collagen scaffolds by 
assembly into tri-layered constructs and then cusps seeded with autologous stem cells as 
described in the current study. After conditioning in bioreactors for 1-2  weeks for stem 
cell pre-differentiation  into  VIC-like  cells,  the  patient-tailored  engineered  heart  
valve  would  be  surgically implanted.  
 Our working premise is that the extracellular matrix of cardiovascular tissues 
provides ideal scaffolds for valvular tissue engineering.  Previously we described 
development of collagen scaffolds to  be  used  as  the  fibrous  layers  of  the  heart  
valve  cusps  [14] and a scaffold to be used as a spongiosa layer for heart valve tissue 
engineering. When the spongy scaffold is seeded with cells and conditioned in 
bioreactors, such scaffold-enclosed “cell pockets” maintained cell viability and allowed 
transmission of mechanical cues to induce stem cells differentiation into VIC-like cells.  
However, with differentiation of the stem cells into VIC-like cells, and remodeling of the 
scaffold, the problem of overproduction and continued growth of the valve is possible 
[15]. The patient would have to be monitored for valve hypertrophy, whereas to mitigate 
this occurrence, growth factors may need to be incorporated into the scaffold, with the 
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dosage, release, and duration optimized for a balance between tissue growth and 
remodeling. To ascertain the extent of valve growth, accelerated aging tests must be 
preformed, whereby in vitro bioreactor studies in conjunction with growth factor studies 
could elucidate how the valve will remodel and possibly grow as it ages.  
  
7.5      Conclusions 
This  study  is  a  stepping  stone  towards  development  of  a  novel  approach  to  
heart  valve  tissue engineering. The scaffolds  we have previously developed were  
assembled  into  anatomically  analogous  3-D  heart  valve  shapes  using  novel  protein-
based glue, seeded with stem cells and conditioned in bioreactors to induce stem cell 
differentiation. It can be concluded that histiologically similar mechanical stimuli offered 
by our TEHV encourages differentiation of stem cells into activated valvular interstitial 
cells.    
While many aspects and details need to be optimized as far as scaffold assembly 
and animal testing are concerned, this approach appears promising for our envisioned 
translational scenario.     
 
7.6 References 
1. Simionescu, D.T., J.J. Lovekamp, and N.R. Vyavahare, Degeneration of 
bioprosthetic heart valve cusp and wall tissues is initiated during tissue 
preparation: an ultrastructural study. J Heart Valve Dis, 2003. 12(2): p. 226-34. 
 
2. Simionescu, D.T., J.J. Lovekamp, and N.R. Vyavahare, Extracellular matrix 
degrading enzymes are active in porcine stentless aortic bioprosthetic heart 
valves. J Biomed Mater Res A, 2003. 66(4): p. 755-63. 
 177 
3. Simionescu, D.T., J.J. Lovekamp, and N.R. Vyavahare, Glycosaminoglycan-
degrading enzymes in porcine aortic heart valves: implications for bioprosthetic 
heart valve degeneration. J Heart Valve Dis, 2003. 12(2): p. 217-25. 
 
4. Mendelson, K. and F.J. Schoen, Heart valve tissue engineering: concepts, 
approaches, progress, and challenges. Ann Biomed Eng, 2006. 34(12): p. 1799-
819. 
 
5. Latif, N., et al., Characterization of structural and signaling molecules by human 
valve interstitial cells and comparison to human mesenchymal stem cells. J Heart 
Valve Dis, 2007. 16(1): p. 56-66. 
 
6. Ku, C.H., et al., Collagen synthesis by mesenchymal stem cells and aortic valve 
interstitial cells in response to mechanical stretch. Cardiovasc Res, 2006. 71(3): 
p. 548-56. 
 
7. Taylor, P.M., et al., The cardiac valve interstitial cell. Int J Biochem Cell Biol, 
2003. 35(2): p. 113-8. 
 
8. Liu, A.C., V.R. Joag, and A.I. Gotlieb, The emerging role of valve interstitial cell 
phenotypes in regulating heart valve pathobiology. Am J Pathol, 2007. 171(5): p. 
1407-18. 
 
9. Fang, N.T., et al., Construction of tissue-engineered heart valves by using 
decellularized scaffolds and endothelial progenitor cells. Chin Med J (Engl), 
2007. 120(8): p. 696-702. 
 
10. Visconti, R.P., et al., An in vivo analysis of hematopoietic stem cell potential: 
hematopoietic origin of cardiac valve interstitial cells. Circ Res, 2006. 98(5): p. 
690-6. 
 
11. Schmidt, D., et al., Engineering of biologically active living heart valve leaflets 
using human umbilical cord-derived progenitor cells. Tissue Eng, 2006. 12(11): 
p. 3223-32. 
 
12. Fraser, J.K., et al., Fat tissue: an underappreciated source of stem cells for 
biotechnology. Trends Biotechnol, 2006. 24(4): p. 150-4. 
 
13. Tedder, M.E., et al., Stabilized collagen scaffolds for heart valve tissue 
engineering. Tissue Eng Part A, 2009. 15(6): p. 1257-68. 
 
14. Tedder, M.E., et al., Stabilized Collagen Scaffolds for Heart Valve Tissue 
Engineering. Tissue Eng Part A, 2008. 
 178 
15. Neuenschwander, S. and S.P. Hoerstrup, Heart valve tissue engineering. Transpl 










8.1       Conclusions 
 Tissue engineering, the emerging science of combining scaffolds, cells and 
specific mechanical and biochemical signals is feasible and holds great promise for 
treatment of heart valve disease [1, 2]. Recognizing the vital importance of the three 
leaflet layers [3], the outstanding hemodynamics of natural valve homografts [4] and the 
need for reconstruction of the physiologic valve design, we hypothesize that combination 
of four elements can be utilized for tissue engineering of the “ideal” aortic heart valve: A) 
Constructs made from partially stabilized collagenous scaffolds, B) Anatomically 
analogous 3-D heart valve shapes made from tri-layered structures that mimic the native 
heart valve histo-architecture, C) Autologous multipotent bone marrow derived stem cells 
for repopulation and remodeling. These ideas were tested in the work presented here, 
allowing us to draw the following conclusions: 
 We could successfully decellularize pericardium and pulmonary arteries to yield 
pure, porous, collagenous scaffolds 
 Scaffold fixation with PGG: 
o Partially stabilized the fibrous collagen scaffolds 
o Allowed for cell infiltration in vivo 
 Scaffold adherence with BTglue showed that: 
o Our novel glue was able to adhere the scaffold together 
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o Was non toxic to cells 
 Molding of native aortic heart valves with liquid silicone was: 
o Able to duplicate the shape and fine corrugations of the individual leaflets 
o Served as a platform on which the collagenous scaffolds could be molded 
o The formed collagenous scaffolds could be combined to form a tri-layered 
construct that mimics the native histo-architecture of an aortic heart valve 
o The formed valve construct functioned comparably to a native aortic valve 
during bioreactor testing 
 Bioreactor testing of stem cell-seeded tri-layered scaffolds 
o Supported cell growth and survival 
o May possibly support stem cell differentiation into valvular interstitial-like 
cells 
Therefore, our tissue engineered heart valve replacement approaches hold promise to 
create a living heart valve that can potentially grow with the patient. 
 
 
8.2      Recommendations for Future Work 
 As this project is still in its early stages, there is much work to be done to 
optimize the entire process. At each step in the process there are aspects that must be 
investigated in order to make this a viable process that may be utilized in a clinical 
setting. 
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1) The use of a fibrous scaffold with elastin (not removing the elastin from the 
pericardium during the scaffold preparation process is one possibility) can be 
investigated for the use of the ventricularis. 
2) The glycosaminoglycan (GAG) content should be evaluated in the fibrous scaffolds. 
3) The GAG content in the sponsiosa must be augmented to better approximate the 
GAG content in the native aortic valve. 
4) In terms of the fixation process, a better balance must be established between cell 
toxicity, stability, and degradation afforded by PGG cross-linking. 
a) In addition, another cross-linking chemical should be evaluated (such as N-(3-
dimethylaminopropyl)-Nethylcarbodiimide (EDC)) to augment PGG and aid in 
better establishing this balance 
5) In terms of gluing: 
a) Alternative polymerizing agents (other than Glut) can be investigated that could 
minimize the deleterious effects of Glut. 
b) If Glut is still utilized, the neutralization process should be improved to minimize 
the calcification caused by Glut. 
c) The elasticity of the glue should be increased to better match the scaffold 
properties and thus decrease stresses placed of the scaffold due to the glue. 
6) In terms of the molding and assembly process: 
a) A computer aided system should be utilized to form the 3-D rendering of the 
aortic valve that may be used for molding of the tissue scaffolds 
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b) A rapid prototyping interface should be implemented to process the solid molds 
(this will replace the silicone molding, that cannot be utilized in a clinical setting) 
c) How the valve is assembled, considering how much tissue is used for the leaflets 
must be addressed. 
d) Dr. Ivan Vesely maintains that a precise central gap is key to valve function [5], 
therefore amount of tissue used, suture positions, glue amounts, and leaflet 
orientation is key.  
e) Optimizing BTglue adhering locations must also be evaluated and perfected, by 
assessing how much BTglue to use, where it should be applied (at edges of cusps, 
at junction of leaflet and aortic arch), and application procedures (when in the 
assembly process to apply BTglue).   
f) Once the valve leaflets are constructed, a mechanism by which the valve construct 
can be mounted must be tested and perfected, by which either mounting rings, 
stents, or direct mounting either with sutures,  BTglue, or a combination of the 
two should be evaluated.  
7) For stem cell seeding and differentiation, 
a) Different sources for stem cells should be investigated (such as adipose-derived 
stem cells) 
b) Biochemical and further mechanical factors should be implemented that influence 
differentiation 
c) Fundamental studies on native VICs should be performed to establish a standard 
by which the cells we use for seeding should be compared. 
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8) In further bioreactor studies, 
a) Long-term  bioreactor experiments should be performed to evaluate the 
mechanics of the valve over time, as well as stem cell differentiation and 
remodeling potential of our scaffolds 
b) The interface between the surface of the scaffold and blood should be addressed, 
whereby the physical and chemical structure of the surface is ascertained via 
atomic force microscopy(AFM) studies, and bioreactor functionality studies 
whereby the fluid environment around the construct is more closely representative 
of the in vivo environment in which it will be implanted to assess hemolysis and 
thrombogenicity 
c) The valve must be endothelialized, to mimic the surface characteristics of a native 
valve and potentially alleviate hemolytic and thrombogenic problems associated 
with blood/biomaterial interactions 
9) Once these points are addressed, large animal studies (preferably primate 




Figure 8.1: Translational Scenario for Patient-Tailored Heart Valve Tissue Engineering 
 
 
Overall, this translational scenario will cost no more than the currently available 
bioprosthetic heart valve, which currently range from anywhere between $5,000 and 
$20,000 [6]. High initial costs will include the imaging software and the rapid 
prototyping machine for steriolithography for actual manufacturing. The highest 
recurring costs for each patient will be the CT scans for imaging, but even current 
patients receiving a valve replacement necessitate scans. All other aspects of the process 
will incur will monetary requirements, while the benefits of receiving a patient-tailored 
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